

COVID-19 Correlates of Risk Analysis Report
MockCOVE Study

USG COVID-19 Response Biostatistics Team

September 28, 2021

Contents

1	Disclaimers	15
2	Summary Tables	17
2.1	Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	17
2.2	Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	19
2.3	Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort	20
2.4	Availability of immunogenicity data by case status	21
2.5	Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)	22
2.6	Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)	24
2.7	Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)	26
3	Graphical Descriptions of Antibody Marker Data	29
3.1	Boxplots	30
3.2	Weighted RCDF plots	34
3.3	Weighted RCDF plots of threshold correlate concentration for vaccine efficacy	38
3.4	Spaghetti plots	46
3.5	Violin and line plots	47
3.6	Scatter plots	271
4	Graphical Descriptions of Time to Event Data	303
5	Day D29 Univariate CoR: Cox Models of Risk	305
5.1	Hazard ratios	305
5.2	Marginalized risk and controlled vaccine efficacy plots	310
6	Day D57 Univariate CoR: Cox Models of Risk	335
6.1	Hazard ratios	335
6.2	Marginalized risk and controlled vaccine efficacy plots	340

7 Univariate CoR: Nonparametric Threshold Modeling ($\geq s$)	365
7.1 Plots and Tables with estimates and pointwise confidence intervals for Day 57	366
7.2 Plots and Tables with estimates and pointwise confidence intervals for Day 57 (monotone-corrected)	371
7.3 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	376
7.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	381
7.5 Plots and Tables with estimates and simultaneous confidence intervals for Day 57 (monotone-corrected)	386
7.6 Plots and Tables with estimates and simultaneous confidence intervals for Day 57 (monotone-corrected)	391
7.7 Plots and Tables with estimates and simultaneous confidence intervals for Day 29 (monotone-corrected)	396
7.8 Plots and Tables with estimates and simultaneous confidence intervals for Day 29 (monotone-corrected)	401
8 Univariate CoR: Nonparametric Threshold Modeling ($\leq s$)	407
9 Day D29 Univariate CoR: Nonlinear modeling	409
10 Day D57 Univariate CoR: Nonlinear modeling	415
11 Appendix	421

List of Tables

2.1	Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	17
2.2	Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	19
2.3	Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort	20
2.4	Availability of immunogenicity data by case status	21
2.5	Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)	22
2.6	Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)	24
2.7	Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)	26
5.1	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	305
5.2	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*	306
5.3	Analysis of Day 29 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.	310
5.4	Marginalized cumulative risk by Day 192 as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates)	314
5.5	Controlled VE as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).	315
5.6	Controlled VE with sensitivity analysis as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates)	316
5.7	Marginalized cumulative risk by Day 192 as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates)	320
5.8	Controlled VE as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).	321

5.9 Controlled VE with sensitivity analysis as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	322
5.10 Marginalized cumulative risk by Day 192 as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	326
5.11 Controlled VE as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).	327
5.12 Controlled VE with sensitivity analysis as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	328
5.13 Marginalized cumulative risk by Day 192 as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	332
5.14 Controlled VE as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).	333
5.15 Controlled VE with sensitivity analysis as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	334
 6.1 Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	335
6.2 Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*	336
6.3 Analysis of Day 57 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.	340
6.4 Marginalized cumulative risk by Day 164 as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	344
6.5 Controlled VE as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).	345
6.6 Controlled VE with sensitivity analysis as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	346
6.7 Marginalized cumulative risk by Day 164 as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	350
6.8 Controlled VE as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).	351

6.9 Controlled VE with sensitivity analysis as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	352
6.10 Marginalized cumulative risk by Day 164 as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	356
6.11 Controlled VE as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).	357
6.12 Controlled VE with sensitivity analysis as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	358
6.13 Marginalized cumulative risk by Day 164 as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	362
6.14 Controlled VE as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).	363
6.15 Controlled VE with sensitivity analysis as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	364
 7.1 Table of risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with pointwise 95% confidence intervals.	367
7.2 Table of risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with pointwise 95% confidence intervals.	368
7.3 Table of risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals.	369
7.4 Table of risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals.	370
7.5 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with pointwise 95% confidence intervals.	372
7.6 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with pointwise 95% confidence intervals.	373
7.7 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals.	374
7.8 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals.	375
7.9 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with pointwise 95% confidence intervals.	377
7.10 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with pointwise 95% confidence intervals.	378
7.11 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals.	379

7.12 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals.	380
7.13 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with pointwise 95% confidence intervals.	382
7.14 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with pointwise 95% confidence intervals.	383
7.15 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals.	384
7.16 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals.	385
7.17 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals.	387
7.18 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals.	388
7.19 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals.	389
7.20 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals.	390
7.21 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals.	392
7.22 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals.	393
7.23 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals.	394
7.24 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals.	395
7.25 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals.	397
7.26 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals.	398
7.27 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals.	399
7.28 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals.	400
7.29 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals.	402
7.30 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals.	403
7.31 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals.	404
7.32 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals.	405

List of Figures

3.1	Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.	30
3.2	Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm.	31
3.3	Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.	32
3.4	Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm.	33
3.5	RCDF plots for D57 Ab markers by treatment arm.	34
3.6	RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm.	35
3.7	RCDF plots for D29 Ab markers by treatment arm.	36
3.8	RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm.	37
3.9	Marker RCDF of D57 anti-Spike binding Ab: vaccine arm	38
3.10	Marker RCDF of D57 anti-RBD binding Ab: vaccine arm	39
3.11	Marker RCDF of D57 PsV-nAb ID50: vaccine arm	40
3.12	Marker RCDF of D57 PsV-nAb ID80: vaccine arm	41
3.13	Marker RCDF of D29 anti-Spike binding Ab: vaccine arm	42
3.14	Marker RCDF of D29 anti-RBD binding Ab: vaccine arm	43
3.15	Marker RCDF of D29 PsV-nAb ID50: vaccine arm	44
3.16	Marker RCDF of D29 PsV-nAb ID80: vaccine arm	45
3.17	Spaghetti Plots of Marker Trajectory: vaccine arm	46
4.1	Distribution of the number of days to COVID endpoints, vaccine arm, baseline negative.	303
5.1	Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.	307
5.2	Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	308
5.3	Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	308

5.4 Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	309
5.5 Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	309
5.6 Marginalized cumulative risk curves (= s).	311
5.7 Controlled VE curves (= s).	312
5.8 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	313
5.9 Marginalized cumulative risk curves (= s).	317
5.10 Controlled VE curves (= s).	318
5.11 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	319
5.12 Marginalized cumulative risk curves (= s).	323
5.13 Controlled VE curves (= s).	324
5.14 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	325
5.15 Marginalized cumulative risk curves (= s).	329
5.16 Controlled VE curves (= s).	330
5.17 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	331
 6.1 Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.	337
6.2 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	338
6.3 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	338
6.4 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	339
6.5 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	339
6.6 Marginalized cumulative risk curves (= s).	341
6.7 Controlled VE curves (= s).	342
6.8 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	343
6.9 Marginalized cumulative risk curves (= s).	347
6.10 Controlled VE curves (= s).	348
6.11 Marginalized cumulative risk curves and controlled VE curves ($>=s$).	349
6.12 Marginalized cumulative risk curves (= s).	353
6.13 Controlled VE curves (= s).	354

6.14 Marginalized cumulative risk curves and controlled VE curves ($\geq s$).	355
6.15 Marginalized cumulative risk curves ($= s$).	359
6.16 Controlled VE curves ($= s$).	360
6.17 Marginalized cumulative risk curves and controlled VE curves ($\geq s$).	361
7.1 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.	367
7.2 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.	368
7.3 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.	369
7.4 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.	370
7.5 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	372
7.6 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	373
7.7 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	374
7.8 Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	375
7.9 Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	377
7.10 Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	378
7.11 Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	379

7.12	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	380
7.13	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	382
7.14	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	383
7.15	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	384
7.16	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	385
7.17	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	387
7.18	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	388
7.19	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	389
7.20	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	390
7.21	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	392
7.22	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	393
7.23	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	394

7.24	Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	395
7.25	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	397
7.26	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	398
7.27	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	399
7.28	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	400
7.29	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	402
7.30	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	403
7.31	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	404
7.32	Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.	405
9.1	Marginalized risk as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3.	410
9.2	Marginalized risk as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.	411

9.3 Marginalized risk as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 2.4.	412
9.4 Marginalized risk as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 15.	413
10.1 Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3.	416
10.2 Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.	417
10.3 Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 2.4.	418
10.4 Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 15.	419

Chapter 1

Disclaimers

The data presented in the analysis are provided to NIAID in accordance with Clinical Trial Agreement between the parties. The study was funded in part by BARDA under Government Contract No. 75A50120C00034.

Statistical Analysis Plan

The SAP is available at <https://doi.org/10.6084/m9.figshare.13198595>

Reproducibility Notice

This project integrates the virtual environments framework provided by the `renv` package for computational reproducibility. By taking this approach, all results are generated using a consistent versioning of both R and several R packages. This version of the report was built with R version 4.0.4 (2021-02-15), `pandoc` version 2.2, and the following R packages:

package	version	source
bookdown	0.21.7	Github (<code>rstudio/bookdown@0cec2fd</code>)
bslib	0.2.4.9002	Github (<code>rstudio/bslib@c7835c2</code>)
data.table	1.14.0	CRAN (R 4.0.4)
delayed	0.4.0	Github (<code>tlverse/delayed@f415340</code>)
devtools	2.3.2	CRAN (R 4.0.4)
dplyr	1.0.5	CRAN (R 4.0.4)
ggplot2	3.3.3	CRAN (R 4.0.4)
hal9001	0.4.0	Github (<code>tlverse/hal9001@b41ed5d</code>)
haldensify	0.1.5	Github (<code>nhejazi/haldensify@16350cc</code>)
here	1.0.1	CRAN (R 4.0.4)
kableExtra	1.3.4	CRAN (R 4.0.4)
knitr	1.31	CRAN (R 4.0.4)
latex2exp	0.5.0	CRAN (R 4.0.4)
mvtnorm	1.1-1	CRAN (R 4.0.4)
origami	1.0.3	CRAN (R 4.0.4)
readr	1.4.0	CRAN (R 4.0.4)
rmarkdown	2.7.4	Github (<code>rstudio/rmarkdown@a11240d</code>)
skimr	2.1.3	CRAN (R 4.0.4)
sl3	1.4.3	Github (<code>tlverse/sl3@982f4d6</code>)
stringr	1.4.0	CRAN (R 4.0.4)
SuperLearner	2.0-28	CRAN (R 4.0.4)
svyVGAM	1.0	CRAN (R 4.0.4)
tibble	3.1.1	CRAN (R 4.0.4)

package	version	source
tidyr	1.1.3	CRAN (R 4.0.4)
txshift	0.3.6	Github (nhejazi/txshift@c0f572a)
VGAM	1.1-5	CRAN (R 4.0.4)
xtable	1.8-4	CRAN (R 4.0.4)

To get started with using this project and its `renv` package library, we first recommend briefly reviewing the [renv collaboration guide](#).



Chapter 2

Summary Tables

2.1 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Table 2.1: Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 747)	Placebo (N = 138)	Total (N = 885)
Age			
Age < 65	357 (47.8%)	72 (52.2%)	429 (48.5%)
Age ≥ 65	390 (52.2%)	66 (47.8%)	456 (51.5%)
Mean (Range)	58.5 (18.0, 85.0)	58.3 (18.0, 85.0)	58.5 (18.0, 85.0)
BMI			
Mean ± SD	29.7 ± 6.6	31.4 ± 6.3	30.0 ± 6.6
Risk for Severe Covid-19			
At-risk	381 (51.0%)	71 (51.4%)	452 (51.1%)
Not at-risk	366 (49.0%)	67 (48.6%)	433 (48.9%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	185 (24.8%)	36 (26.1%)	221 (25.0%)
Age < 65 Not at-risk	172 (23.0%)	36 (26.1%)	208 (23.5%)
Age ≥ 65	390 (52.2%)	66 (47.8%)	456 (51.5%)
Sex			
Female	427 (57.2%)	75 (54.3%)	502 (56.7%)
Male	320 (42.8%)	63 (45.7%)	383 (43.3%)
Hispanic or Latino ethnicity			
Hispanic or Latino	99 (13.3%)	20 (14.5%)	119 (13.4%)
Not Hispanic or Latino	623 (83.4%)	113 (81.9%)	736 (83.2%)
Not reported and unknown	25 (3.3%)	5 (3.6%)	30 (3.4%)
Race			
White	397 (53.1%)	74 (53.6%)	471 (53.2%)
Black or African American	184 (24.6%)	40 (29.0%)	224 (25.3%)
Asian	56 (7.5%)	10 (7.2%)	66 (7.5%)
American Indian or Alaska Native	16 (2.1%)	2 (1.4%)	18 (2.0%)
Native Hawaiian or Other Pacific Islander	17 (2.3%)	2 (1.4%)	19 (2.1%)

Table 2.1: (*continued*)

Characteristics	Vaccine (N = 747)	Placebo (N = 138)	Total (N = 885)
Multiracial	57 (7.6%)	8 (5.8%)	65 (7.3%)
Other	16 (2.1%)	1 (0.7%)	17 (1.9%)
Not reported and unknown	4 (0.5%)	1 (0.7%)	5 (0.6%)
White Non-Hispanic	370 (49.5%)	63 (45.7%)	433 (48.9%)
Communities of Color	377 (50.5%)	75 (54.3%)	452 (51.1%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

2.2 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Table 2.2: Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 234)	Placebo (N = 241)	Total (N = 475)
Age			
Age < 65	114 (48.7%)	120 (49.8%)	234 (49.3%)
Age ≥ 65	120 (51.3%)	121 (50.2%)	241 (50.7%)
Mean (Range)	58.3 (18.0, 85.0)	56.3 (18.0, 85.0)	57.3 (18.0, 85.0)
BMI			
Mean ± SD	29.7 ± 7.5	30.0 ± 6.6	29.9 ± 7.0
Risk for Severe Covid-19			
At-risk	111 (47.4%)	117 (48.5%)	228 (48.0%)
Not at-risk	123 (52.6%)	124 (51.5%)	247 (52.0%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	56 (23.9%)	59 (24.5%)	115 (24.2%)
Age < 65 Not at-risk	58 (24.8%)	61 (25.3%)	119 (25.1%)
Age ≥ 65	120 (51.3%)	121 (50.2%)	241 (50.7%)
Sex			
Female	139 (59.4%)	133 (55.2%)	272 (57.3%)
Male	95 (40.6%)	108 (44.8%)	203 (42.7%)
Hispanic or Latino ethnicity			
Hispanic or Latino	31 (13.2%)	34 (14.1%)	65 (13.7%)
Not Hispanic or Latino	194 (82.9%)	201 (83.4%)	395 (83.2%)
Not reported and unknown	9 (3.8%)	6 (2.5%)	15 (3.2%)
Race			
White	126 (53.8%)	129 (53.5%)	255 (53.7%)
Black or African American	58 (24.8%)	45 (18.7%)	103 (21.7%)
Asian	19 (8.1%)	27 (11.2%)	46 (9.7%)
American Indian or Alaska Native	10 (4.3%)	7 (2.9%)	17 (3.6%)
Native Hawaiian or Other Pacific Islander	4 (1.7%)	2 (0.8%)	6 (1.3%)
Multiracial	10 (4.3%)	16 (6.6%)	26 (5.5%)
Other	7 (3.0%)	13 (5.4%)	20 (4.2%)
Not reported and unknown		2 (0.8%)	2 (0.4%)
White Non-Hispanic	118 (50.4%)	121 (50.2%)	239 (50.3%)
Communities of Color	116 (49.6%)	120 (49.8%)	236 (49.7%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

2.3 Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort

Table 2.3: Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort

Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort Sample Sizes (N=1360 Participants) (Moderna Trial)																		
	Baseline SARS-CoV-2 Negative									Baseline SARS-CoV-2 Positive								
	1	2	3	4	5	6	7	8	9	1	2	3	4	5	6	7	8	9
Vaccine																		
Day 29 Cases	8	2	3	18	7	12	6	0	3	0	0	2	0	0	0	0	1	0
Day 57 Cases	8	2	1	18	7	9	4	0	3	0	0	2	0	0	0	0	1	0
Non-Cases	153	78	67	235	106	105	69	35	39	48	24	23	72	32	35	26	12	11
Placebo																		
Day 29 Cases	141	48	87	329	109	243	77	31	55	0	0	1	1	1	1	1	0	0
Day 57 Cases	132	37	61	306	93	198	72	27	42	0	0	1	1	1	1	1	0	0
Non-Cases	21	16	16	34	16	18	9	2	3	43	19	22	77	39	38	32	16	9

Demographic covariate strata:

1. Age ≥ 65 , Minority
2. Age < 65 , At risk, Minority
3. Age < 65 , Not at risk, Minority
4. Age ≥ 65 , Non-Minority
5. Age < 65 , At risk, Non-Minority
6. Age < 65 , Not at risk, Non-Minority
7. Age ≥ 65 , Unknown
8. Age < 65 , At risk, Unknown
9. Age < 65 , Not at risk, Unknown

Minority includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders.

Non-Minority includes all other races with observed race (Asian, Multiracial, White, Other) and observed ethnicity Not Hispanic or Latino. Participants not classifiable as Minority or Non-Minority because of unknown, unreported or missing were not included.

Observed = Numbers of participants sampled into the subcohort within baseline covariate strata.

Estimated = Estimated numbers of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.

2.4 Availability of immunogenicity data by case status

Table 2.4: Availability of immunogenicity data by case status

Case	---	--+	-+-	-++	+--	+--	++-	+++
Vaccine								
Day 29 Cases	1	0	0	0	0	0	0	59
Day 57 Cases	0	0	0	0	0	0	0	52
Intercurrent Cases	1	0	0	0	0	0	0	7
Placebo								
Day 29 Cases	49	0	0	0	0	0	0	1120
Day 57 Cases	42	0	0	0	0	0	0	968
Intercurrent Cases	6	0	0	0	0	0	0	146

The + (available) and - (unavailable) in the column labels refer to the availability of the baseline, D29 and D57 markers, respectively.

2.5 Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)

Table 2.5: Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)


Visit	Marker	Baseline SARS-CoV-2 Negative Vaccine Recipients						Comparison	
		Cases*		Non-Cases/Control				Resp Rate Difference	GMTR/GMCR
	N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC			
Day 29	Pseudovirus-nAb cID80	59	35.6/60 = 59.3% (46.2%, 71.3%)	21.18 (17.33, 25.87)	744	6530.6/11070 = 59.0% (54.4%, 63.4%)	25.97 (23.98, 28.13)	0 (-0.14, 0.13)	0.82 (0.66, 1.01)
Day 29	Pseudovirus-nAb cID50	59	53.9/60 = 89.8% (78.9%, 95.4%)	16.19 (12.51, 20.95)	744	9932/11070 = 89.7% (86.2%, 92.4%)	17.35 (15.85, 18.99)	0 (-0.11, 0.07)	0.93 (0.71, 1.23)
Day 29	Anti RBD IgG (BAU/ml)	59	60/60 = 100.0% (100.0%, 100.0%)	456.66 (292.67, 712.53)	744	10896.8/11070 = 98.4% (96.6%, 99.3%)	473.53 (412.98, 542.96)	0.02 (0.01, 0.03)	0.96 (0.61, 1.54)
Day 29	Anti Spike IgG (BAU/ml)	59	60/60 = 100.0% (100.0%, 100.0%)	236.57 (169.47, 330.25)	744	10981.5/11070 = 99.2% (97.7%, 99.7%)	266.03 (238.38, 296.89)	0.01 (0, 0.02)	0.89 (0.63, 1.26)
Day 29	Anti N IgG (BAU/ml)	59	35.6/60 = 59.3% (46.2%, 71.3%)	39.18 (24.94, 61.55)	744	6848.9/11070 = 61.9% (57.3%, 66.2%)	36.77 (31.08, 43.49)	-0.03 (-0.16, 0.1)	1.07 (0.66, 1.73)
Day 57	Pseudovirus-nAb cID80	52	52/52 = 100.0% (100.0%, 100.0%)	408.70 (310.06, 538.71)	744	11065/11065 = 100.0% (100.0%, 100.0%)	564.67 (511.70, 623.12)	0 (0, 0)	0.72 (0.54, 0.97)
Day 57	Pseudovirus-nAb cID50	52	52/52 = 100.0% (100.0%, 100.0%)	320.14 (230.41, 444.83)	744	11065/11065 = 100.0% (100.0%, 100.0%)	427.25 (383.62, 475.84)	0 (0, 0)	0.75 (0.53, 1.06)
Day 57	Anti RBD IgG (BAU/ml)	52	52/52 = 100.0% (100.0%, 100.0%)	3325.76 (2232.06, 4955.38)	744	11045.2/11065 = 99.8% (98.7%, 100.0%)	3599.25 (3171.86, 4084.22)	0 (0, 0.01)	0.92 (0.61, 1.40)
Day 57	Anti Spike IgG (BAU/ml)	52	52/52 = 100.0% (100.0%, 100.0%)	1847.33 (1337.98, 2550.57)	744	11065/11065 = 100.0% (100.0%, 100.0%)	2668.40 (2364.64, 3011.17)	0 (0, 0)	0.69 (0.49, 0.98)

Day 57	Anti N IgG (BAU/ml)	52	$37/52 = 71.2\%$ (57.2%, 82.0%)	71.78 (43.87, 117.44)	744	$8998.4/11065 = 81.3\%$ (77.3%, 84.8%)	110.30 (94.07, 129.33)	-0.1 (-0.25, 0.01)	0.65 (0.39, 1.09)
-----------	---------------------	----	------------------------------------	--------------------------	-----	---	---------------------------	-----------------------	----------------------

Cases for Day 29 markers are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline negative per-protocol vaccine recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.6 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)

Table 2.6: Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)


Visit	Marker	Baseline SARS-CoV-2 Positive Vaccine Recipients						Comparison	
		Cases*		Non-Cases/Control		Resp Rate Difference	GMTR/GMCR		
N	Resp rate	N	Resp rate	GMT/GMC					
Day 29	Pseudovirus-nAb cID80	3 (3.3/5 = 66.7% (0.6%, 99.8%)	28.17 (20.25, 39.20)	234 904.7/1218.1 = 74.3% (66.3%, 80.9%)	51.20 (44.64, 58.73)	-0.08 (-0.74, 0.27)	0.55 (0.38, 0.79)		
Day 29	Pseudovirus-nAb cID50	3 (5/5 = 100.0% (100.0%, 100.0%)	37.31 (35.33, 39.40)	234 1159.7/1218.1 = 95.2% (89.2%, 97.9%)	32.70 (28.11, 38.04)	0.05 (0.02, 0.11)	1.14 (0.97, 1.34)		
Day 29	Anti RBD IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	622.59 (124.89, 3103.56)	234 1213.5/1218.1 = 99.6% (97.3%, 99.9%)	823.96 (640.00, 1060.79)	0 (0, 0.03)	0.76 (0.15, 3.84)		
Day 29	Anti Spike IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	180.93 (156.70, 208.91)	234 1209.6/1218.1 = 99.3% (95.1%, 99.9%)	474.27 (397.60, 565.71)	0.01 (0, 0.05)	0.38 (0.30, 0.48)		
Day 29	Anti N IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	220.52 (99.97, 486.42)	234 928.1/1218.1 = 76.2% (68.6%, 82.4%)	70.68 (55.09, 90.70)	0.24 (0.18, 0.31)	3.12 (1.36, 7.15)		
Day 57	Pseudovirus-nAb cID80	3 (5/5 = 100.0% (100.0%, 100.0%)	1156.48 (486.62, 2748.44)	233 1229/1229 = 100.0% (100.0%, 100.0%)	1559.92 (1333.89, 1824.26)	0 (0, 0)	0.74 (0.31, 1.79)		
Day 57	Pseudovirus-nAb cID50	3 (5/5 = 100.0% (100.0%, 100.0%)	493.08 (319.26, 761.53)	233 1229/1229 = 100.0% (100.0%, 100.0%)	1227.59 (1000.73, 1505.88)	0 (0, 0)	0.40 (0.25, 0.65)		
Day 57	Anti RBD IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	15558.50 (14386.64, 16825.81)	233 1229/1229 = 100.0% (100.0%, 100.0%)	8619.19 (7266.78, 10223.28)	0 (0, 0)	1.81 (1.50, 2.18)		
Day 57	Anti Spike IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	4871.27 (3719.87, 6379.06)	233 1229/1229 = 100.0% (100.0%, 100.0%)	5665.25 (4956.22, 6475.72)	0 (0, 0)	0.86 (0.64, 1.16)		

Day	Anti N IgG (BAU/ml)	3	$5/5 = 100.0\%$ (100.0%, 100.0%)	293.21 (150.76, 570.25)	233	$1182.5/1229 = 96.2\%$ (90.6%, 98.5%)	248.12 (202.53, 303.97)	0.04 (0.01, 0.09)	1.18 (0.59, 2.37)
57									

The SAP does not specify correlates analyses in baseline positive vaccine recipients. This table summarizes descriptively the same information for baseline positive vaccine recipients that was summarized for baseline negative vaccine recipients. Cases for Day 29 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol vaccine recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.7 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)

Table 2.7: Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)


Visit	Marker	Baseline SARS-CoV-2 Positive Placebo Recipients						Comparison	
		Cases*		Non-Cases/Control				Resp Rate Difference	GMTR/GMCR
	N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC			
Day 29	Pseudovirus-nAb cID80	5 $3/5 = 60.0\%$ (10.6%, 95.0%)	19.58 (9.63, 39.79)	238 $442.9/1121 = 39.5\%$ (32.4%, 47.1%)	20.38 (17.86, 23.27)	0.2 (-0.29, 0.56)	0.96 (0.47, 1.98)		
Day 29	Pseudovirus-nAb cID50	5 $2/5 = 40.0\%$ (5.0%, 89.4%)	4.46 (1.50, 13.28)	238 $896.5/1121 = 80.0\%$ (72.4%, 85.9%)	11.68 (9.90, 13.77)	-0.4 (-0.75, 0.1)	0.38 (0.13, 1.15)		
Day 29	Anti RBD IgG (BAU/ml)	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	498.48 (77.45, 3208.22)	238 $1060/1121 = 94.6\%$ (88.4%, 97.5%)	306.92 (232.82, 404.62)	0.05 (0.02, 0.12)	1.62 (0.25, 10.67)		
Day 29	Anti Spike IgG (BAU/ml)	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	266.06 (74.76, 946.84)	238 $1085.9/1121 = 96.9\%$ (91.9%, 98.8%)	170.13 (136.41, 212.19)	0.03 (0.01, 0.08)	1.56 (0.43, 5.67)		
Day 29	Anti N IgG (BAU/ml)	5 $3/5 = 60.0\%$ (10.6%, 95.0%)	11.78 (2.03, 68.41)	238 $603/1121 = 53.8\%$ (45.9%, 61.5%)	26.96 (20.32, 35.77)	0.06 (-0.44, 0.42)	0.44 (0.07, 2.60)		
Day 57	Pseudovirus-nAb cID80	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	288.29 (114.87, 723.51)	238 $1119/1119 = 100.0\%$ (100.0%, 100.0%)	462.73 (395.43, 541.48)	0 (0, 0)	0.62 (0.24, 1.58)		
Day 57	Pseudovirus-nAb cID50	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	629.06 (128.64, 3076.16)	238 $1119/1119 = 100.0\%$ (100.0%, 100.0%)	313.97 (258.96, 380.65)	0 (0, 0)	2.00 (0.40, 9.91)		
Day 57	Anti RBD IgG (BAU/ml)	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	1704.47 (253.44, 11462.91)	238 $1119/1119 = 100.0\%$ (100.0%, 100.0%)	2656.74 (2066.29, 3415.92)	0 (0, 0)	0.64 (0.09, 4.39)		
Day 57	Anti Spike IgG (BAU/ml)	5 $5/5 = 100.0\%$ (100.0%, 100.0%)	1648.06 (332.52, 8168.38)	238 $1119/1119 = 100.0\%$ (100.0%, 100.0%)	1953.05 (1538.23, 2479.73)	0 (0, 0)	0.84 (0.17, 4.26)		

Day	Anti N IgG (BAU/ml)	5	$3/5 = 60.0\%$ (10.6%, 95.0%)	49.66 (3.50, 703.93)	238	$865.3/1119 = 77.3\%$ (69.5%, 83.6%)	94.81 (70.11, 128.23)	-0.17 (-0.67, 0.19)	0.52 (0.04, 7.55)
57									

Cases for Day 29 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol placebo recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



MOCK

MOCK

Chapter 3

Graphical Descriptions of Antibody Marker Data

3.1 Boxplots




Figure 3.1: Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.2: Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm.




Figure 3.3: Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.4: Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm.

3.2 Weighted RCDF plots




Figure 3.5: RCDF plots for D57 Ab markers by treatment arm.




Figure 3.6: RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm.




Figure 3.7: RCDF plots for D29 Ab markers by treatment arm.




Figure 3.8: RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm.

3.3 Weighted RCDF plots of threshold correlate concentration for vaccine efficacy




Figure 3.9: Marker RCDF of D57 anti-Spike binding Ab: vaccine arm




Figure 3.10: Marker RCDF of D57 anti-RBD binding Ab: vaccine arm




Figure 3.11: Marker RCDF of D57 PsV-nAb ID50: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY41




Figure 3.12: Marker RCDF of D57 PsV-nAb ID80: vaccine arm




Figure 3.13: Marker RCDF of D29 anti-Spike binding Ab: vaccine arm




Figure 3.14: Marker RCDF of D29 anti-RBD binding Ab: vaccine arm




Figure 3.15: Marker RCDF of D29 PsV-nAb ID₅₀: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY 45




Figure 3.16: Marker RCDF of D29 PsV-nAb ID80: vaccine arm

3.4 Spaghetti plots






Figure 3.17: Spaghetti Plots of Marker Trajectory: vaccine arm

3.5 Violin and line plots




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.1: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.2: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.3: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.4: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)






Figure 2.5.5: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.6: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.7: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.8: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm (version 1)




Figure 2.5.9: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




Figure 2.5.10: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)




Figure 2.5.11: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)




Figure 2.5.12: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)




Figure 2.5.13: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm (version 1)




Figure 2.5.14: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm (version 1)




Figure 2.5.15: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm (version 1)






Figure 2.5.16: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.17: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.18: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.19: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.20: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.21: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.22: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.23: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.24: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm (version 2)




Figure 2.5.25: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)




Figure 2.5.26: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)




Figure 2.5.27: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




Figure 2.5.28: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




Figure 2.5.29: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm (version 2)




Figure 2.5.30: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm (version 2)




Figure 2.5.31: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm (version 2)






Figure 2.5.32: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.33: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.34: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.35: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.36: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.37: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.38: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.39: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.40: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age (version 1)




Figure 2.5.41: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)




Figure 2.5.42: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




Figure 2.5.43: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)




Figure 2.5.44: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)




Figure 2.5.45: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age (version 1)




Figure 2.5.46: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age (version 1)




Figure 2.5.47: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age (version 1)






Figure 2.5.48: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.49: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.50: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.51: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.52: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.53: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.54: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.55: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.56: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age (version 2)




Figure 2.5.57: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)




Figure 2.5.58: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)




Figure 2.5.59: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




Figure 2.5.60: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




Figure 2.5.61: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age (version 2)




Figure 2.5.62: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age (version 2)




Figure 2.5.63: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age (version 2)






Figure 2.5.64: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.65: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.66: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.67: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.68: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.69: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.70: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.71: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.72: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by risk condition (version 1)




Figure 2.5.73: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




Figure 2.5.74: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




Figure 2.5.75: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




Figure 2.5.76: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)




Figure 2.5.77: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by risk condition (version 1)




Figure 2.5.78: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by risk condition (version 1)




Figure 2.5.79: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by risk condition (version 1)






Figure 2.5.80: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.81: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.82: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.83: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.84: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.85: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.86: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.87: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.88: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by risk condition (version 2)




Figure 2.5.89: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




Figure 2.5.90: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




Figure 2.5.91: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




Figure 2.5.92: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




Figure 2.5.93: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by risk condition (version 2)




Figure 2.5.94: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by risk condition (version 2)




Figure 2.5.95: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by risk condition (version 2)






Figure 2.5.96: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.97: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.98: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.99: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 2.5.100: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.101: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.102: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age and risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 2.5.103: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age and risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.104: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age and risk condition (version 1)




Figure 2.5.105: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)




Figure 2.5.106: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)




Figure 2.5.107: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)




Figure 2.5.108: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




Figure 2.5.109: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age and risk condition (version 1)




Figure 2.5.110: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age and risk condition (version 1)




Figure 2.5.111: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age and risk condition (version 1)






Figure 2.5.112: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.113: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.114: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.115: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.116: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 2.5.117: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.118: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 2.5.119: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.120: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age and risk condition (version 2)




Figure 2.5.121: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)




Figure 2.5.122: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)




Figure 2.5.123: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)




Figure 2.5.124: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




Figure 2.5.125: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by age and risk condition (version 2)




Figure 2.5.126: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by age and risk condition (version 2)




Figure 2.5.127: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by age and risk condition (version 2)






Figure 2.5.128: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.129: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.130: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.131: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.132: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.133: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.134: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.135: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.136: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 2.5.137: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 2.5.138: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 2.5.139: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 2.5.140: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 2.5.141: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 2.5.142: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 2.5.143: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by sex assigned at birth (version 1)






Figure 2.5.144: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by sex assigned at birth (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.145: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.146: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.147: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.148: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.149: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.150: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.151: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.152: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 2.5.153: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 2.5.154: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 2.5.155: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 2.5.156: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 2.5.157: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 2.5.158: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 2.5.159: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by sex assigned at birth (version 2)






Figure 2.5.160: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.161: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.162: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.163: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.164: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.165: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.166: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.167: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.168: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 2.5.169: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)




Figure 2.5.170: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 2.5.171: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)




Figure 2.5.172: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 2.5.173: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by race and ethnic group (version 1)




Figure 2.5.174: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 2.5.175: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by race and ethnic group (version 1)






Figure 2.5.176: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.177: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.178: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.179: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.180: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.181: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.182: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.183: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.184: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 2.5.185: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)




Figure 2.5.186: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 2.5.187: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




Figure 2.5.188: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 2.5.189: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by race and ethnic group (version 2)




Figure 2.5.190: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 2.5.191: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by race and ethnic group (version 2)






Figure 2.5.192: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger


Figure 2.5.193: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger


Figure 2.5.194: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)

Binding Antibody to RBD




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.195: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.196: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.197: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.198: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.199: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.200: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.201: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.202: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.203: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.204: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.205: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.206: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 2.5.207: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)






Figure 2.5.208: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.209: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.210: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.211: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.212: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.213: lineplots of PsV Neutralization 50% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.214: lineplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.215: lineplots of PsV Neutralization 80% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 2.5.216: lineplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.217: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.218: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.219: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.220: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.221: violinplots of PsV Neutralization 50% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.222: violinplots of PsV Neutralization 50% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.223: violinplots of PsV Neutralization 80% Titer: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 2.5.224: violinplots of PsV Neutralization 80% Titer: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)

3.6 Scatter plots




Figure 2.6.1: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 1




Figure 2.6.2: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 29




Figure 2.6.3: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 57




Figure 2.6.4: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 1




Figure 2.6.5: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 29




Figure 2.6.6: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 57




Figure 2.6.7: scatterplots of PsV Neutralization 50% Titer vs Age: baseline negative vaccine arm at day 1




Figure 2.6.8: scatterplots of PsV Neutralization 50% Titer vs Age: baseline negative vaccine arm at day 29




Figure 2.6.9: scatterplots of PsV Neutralization 50% Titer vs Age: baseline negative vaccine arm at day 57




Figure 2.6.10: scatterplots of PsV Neutralization 80% Titer vs Age: baseline negative vaccine arm at day 1




Figure 2.6.11: scatterplots of PsV Neutralization 80% Titer vs Age: baseline negative vaccine arm at day 29




Figure 2.6.12: scatterplots of PsV Neutralization 80% Titer vs Age: baseline negative vaccine arm at day 57




Figure 2.6.13: scatterplots of Binding Antibody to Spike vs Age: by arm at day 1




Figure 2.6.14: scatterplots of Binding Antibody to Spike vs Age: by arm at day 29




Figure 2.6.15: scatterplots of Binding Antibody to Spike vs Age: by arm at day 57




Figure 2.6.16: scatterplots of Binding Antibody to RBD vs Age: by arm at day 1




Figure 2.6.17: scatterplots of Binding Antibody to RBD vs Age: by arm at day 29




Figure 2.6.18: scatterplots of Binding Antibody to RBD vs Age: by arm at day 57




Figure 2.6.19: scatterplots of PsV Neutralization 50% Titer vs Age: by arm at day 1




Figure 2.6.20: scatterplots of PsV Neutralization 50% Titer vs Age: by arm at day 29




Figure 2.6.21: scatterplots of PsV Neutralization 50% Titer vs Age: by arm at day 57




Figure 2.6.22: scatterplots of PsV Neutralization 80% Titer vs Age: by arm at day 1




Figure 2.6.23: scatterplots of PsV Neutralization 80% Titer vs Age: by arm at day 29




Figure 2.6.24: scatterplots of PsV Neutralization 80% Titer vs Age: by arm at day 57




Figure 2.6.25: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at Day 29 and Day 57




Figure 2.6.26: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at Day 29 and Day 57




Figure 2.6.27: scatterplots of PsV Neutralization 50% Titer vs Days Since the Day 29 Visit: baseline negative vaccine arm at Day 29 and Day 57




Figure 2.6.28: scatterplots of PsV Neutralization 80% Titer vs Days Since the Day 29 Visit: baseline negative vaccine arm at Day 29 and Day 57




Figure 2.6.29: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at Day 29 and Day 57




Figure 2.6.30: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at Day 29 and Day 57




Figure 2.6.31: scatterplots of PsV Neutralization 50% Titer vs Days Since the Day 29 Visit: by arm at Day 29 and Day 57




Figure 2.6.32: scatterplots of PsV Neutralization 80% Titer vs Days Since the Day 29 Visit: by arm at Day 29 and Day 57

Chapter 4

Graphical Descriptions of Time to Event Data




Figure 4.1: Distribution of the number of days to COVID endpoints, vaccine arm, baseline negative.

MOCK

Chapter 5

Day D29 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

5.1 Hazard ratios

Table 5.1: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

MockCOVE Immunologic Marker	No. cases / No. at-risk**	HR per 10-fold incr. Pt. Est.	95% CI	P-value (2-sided)	q-value ***	FWER
Anti Spike IgG (BAU/ml)	60/11,157	0.30	(0.17-0.53)	<0.001	<0.001	<0.001
Anti RBD IgG (BAU/ml)	60/11,157	0.50	(0.30-0.84)	0.010	<0.001	<0.001
Pseudovirus-nAb cID50	60/11,157	0.43	(0.22-0.85)	0.016	<0.001	<0.001
Pseudovirus-nAb cID80	60/11,157	0.35	(0.18-0.68)	0.002	<0.001	<0.001

*Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. Maximum failure event time 192 days.

**No. at-risk = estimated number in the population for analysis, i.e. baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint or infected through 6 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoint.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).

Table 5.2: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

MockCOVE Immunologic Marker	Tertile	No. cases / No. at-risk**	Attack rate	Pt. Est.	Haz. Ratio 95% CI	P-value (2-sided)	Overall P- value***	Overall q- value †	Overall FWER
Anti Spike IgG (BAU/ml)	Lower	20/3,702	0.0054	1	N/A	N/A	0.003	<0.001	<0.001
	Middle	19/3,705	0.0051	0.56	(0.27-1.13)	0.107			
	Upper	20/3,750	0.0053	0.25	(0.11-0.56)	<0.001			
Anti RBD IgG (BAU/ml)	Lower	26/3,722	0.0070	1	N/A	N/A	0.001	<0.001	<0.001
	Middle	13/3,740	0.0035	0.32	(0.15-0.66)	0.002			
	Upper	20/3,695	0.0054	0.28	(0.13-0.60)	<0.001			
Pseudovirus-nAb cID50	Lower	20/3,690	0.0054	1	N/A	N/A	0.050	<0.001	0.013
	Middle	23/3,749	0.0061	0.97	(0.50-1.90)	0.935			
	Upper	16/3,718	0.0043	0.45	(0.21-0.95)	0.037			
Pseudovirus-nAb cID80	Lower	20/3,754	0.0053	1	N/A	N/A	0.026	<0.001	<0.001
	Middle	26/3,719	0.0070	1.16	(0.61-2.19)	0.653			
	Upper	13/3,685	0.0035	0.45	(0.21-0.95)	0.038			
Placebo		1112/11,426	0.0973						

*Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. Maximum failure event time 192 days. Cutpoints: Anti Spike IgG (BAU/ml) [2.14, 2.65), Anti RBD IgG (BAU/ml) [2.37, 2.98), Pseudovirus-nAb cID50 [1.07, 1.45), Pseudovirus-nAb cID80 [1.26, 1.61), all on the log10 scale.

**No. at-risk = estimated number in the population for analysis, i.e. baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint or infected through 6 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoint.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).




Figure 5.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 29




Figure 5.2: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 29




Figure 5.3: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.




Figure 5.4: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

MOCT

PsV Neutralization 80% Titer: Day 29




Figure 5.5: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.


5.2 Marginalized risk and controlled vaccine efficacy plots

Table 5.3: Analysis of Day 29 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.


	marginalized risk		controlled risk		$e(0,1)^2$	
	ratio $RR_M(0,1)$	Point Est. 95% CI	ratio $RR_C(0,1)^1$	Point Est. 95% CI	Point Est. 95% CI UL	
Anti Spike IgG (BAU/ml)	0.25	0.13–0.69	0.34	0.17–0.92	7.4	2.3
Anti RBD IgG (BAU/ml)	0.29	0.16–0.73	0.38	0.21–0.97	6.4	2.1
Pseudovirus-nAb CID50	0.45	0.21–0.80	0.60	0.29–1.07	3.9	1.8
Pseudovirus-nAb CID80	0.45	0.24–0.81	0.60	0.32–1.08	3.9	1.8

¹Conservative (upper bound) estimate assuming unmeasured confounding at level $RR_{UD}(0,1) = RR_{EU}(0,1) = 2$ and thus $B(0,1) = 4/3$.

²E-values are computed for upper tertile ($s = 1$) vs. lower tertile ($s = 0$) biomarker subgroups after controlling for MinorityInd + HighRiskInd + riskscore; UL = upper limit.




(a) Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 192 as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3$.

Figure 5.6: Marginalized cumulative risk curves ($=s$).



(a) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3$.



(b) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3$.

Figure 5.7: Controlled VE curves ($=s$).




Figure 5.8: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 5.4: Marginalized cumulative risk by Day 192 as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.0549 (.0136,.1427)	37	.0184 (.0086,.0334)	249	.0069 (.0057,.0085)	1412	.0028 (.0018,.0041)
4	.0528 (.0134,.1364)	40	.0176 (.0084,.0315)	269	.0067 (.0056,.0080)	1528	.0027 (.0017,.0040)
5	.0509 (.0132,.1303)	44	.0169 (.0083,.0298)	291	.0064 (.0055,.0076)	1653	.0026 (.0016,.0039)
5	.0490 (.0129,.1243)	47	.0163 (.0081,.0281)	315	.0061 (.0053,.0072)	1785	.0025 (.0015,.0039)
6	.0471 (.0127,.1186)	51	.0156 (.0080,.0265)	333	.0060 (.0051,.0069)	1789	.0025 (.0015,.0039)
6	.0454 (.0125,.1131)	56	.0150 (.0079,.0251)	341	.0059 (.0050,.0068)	1936	.0024 (.0014,.0038)
7	.0437 (.0123,.1078)	60	.0144 (.0077,.0237)	369	.0056 (.0048,.0064)	2095	.0023 (.0013,.0037)
7	.0420 (.0121,.1027)	64	.0140 (.0076,.0226)	399	.0054 (.0045,.0061)	2228	.0022 (.0012,.0037)
8	.0404 (.0119,.0977)	65	.0138 (.0076,.0223)	432	.0052 (.0043,.0059)	2267	.0022 (.0012,.0037)
8	.0389 (.0117,.0930)	70	.0133 (.0075,.0211)	468	.0050 (.0040,.0056)	2453	.0021 (.0012,.0036)
9	.0374 (.0115,.0884)	76	.0128 (.0074,.0199)	475	.0050 (.0040,.0056)	2655	.0020 (.0011,.0035)
10	.0360 (.0113,.0840)	82	.0123 (.0072,.0188)	500	.0048 (.0038,.0055)	2873	.0019 (.0010,.0035)
11	.0346 (.0112,.0798)	84	.0121 (.0072,.0185)	506	.0048 (.0038,.0054)	3109	.0019 (.0010,.0034)
11	.0333 (.0110,.0758)	89	.0118 (.0071,.0178)	548	.0046 (.0036,.0053)	3364	.0018 (.0009,.0033)
12	.0320 (.0108,.0720)	96	.0113 (.0070,.0168)	593	.0044 (.0034,.0051)	3640	.0017 (.0009,.0033)
13	.0308 (.0106,.0683)	104	.0109 (.0069,.0159)	641	.0042 (.0032,.0049)	3939	.0016 (.0008,.0032)
15	.0296 (.0104,.0647)	113	.0104 (.0068,.0150)	693	.0041 (.0030,.0048)	4263	.0016 (.0008,.0032)
16	.0284 (.0103,.0614)	121	.0101 (.0067,.0143)	694	.0041 (.0030,.0048)	4613	.0015 (.0007,.0031)
17	.0273 (.0101,.0582)	122	.0100 (.0067,.0142)	751	.0039 (.0028,.0047)	4992	.0015 (.0007,.0031)
18	.0263 (.0099,.0551)	132	.0096 (.0066,.0134)	813	.0037 (.0027,.0046)	5401	.0014 (.0006,.0030)
20	.0253 (.0098,.0522)	143	.0092 (.0064,.0126)	879	.0036 (.0025,.0045)	5845	.0013 (.0006,.0029)
22	.0243 (.0096,.0494)	155	.0089 (.0063,.0119)	952	.0035 (.0024,.0045)	6325	.0013 (.0006,.0029)
23	.0233 (.0095,.0467)	168	.0085 (.0062,.0113)	1000	.0034 (.0023,.0044)	6844	.0012 (.0005,.0028)
25	.0224 (.0093,.0442)	181	.0082 (.0061,.0106)	1030	.0033 (.0022,.0044)	7407	.0012 (.0005,.0028)
27	.0215 (.0091,.0418)	196	.0078 (.0060,.0100)	1114	.0032 (.0021,.0043)	8015	.0011 (.0005,.0028)
30	.0207 (.0090,.0395)	212	.0075 (.0059,.0095)	1206	.0031 (.0020,.0042)	8673	.0011 (.0004,.0027)
32	.0199 (.0088,.0374)	224	.0073 (.0058,.0091)	1294	.0029 (.0019,.0042)	9385	.0010 (.0004,.0027)
35	.0191 (.0087,.0353)	230	.0072 (.0058,.0089)	1305	.0029 (.0019,.0041)	10156	.0010 (.0004,.0026)

Table 5.5: Controlled VE as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.4618 (-0.3675,.8650)	40	.8271 (0.6977,.9164)	291	.9373 (0.9275,.9451)	1785	.9756 (0.9624,.9853)
4	.4817 (-0.3071,.8672)	44	.8339 (0.7143,.9178)	315	.9398 (0.9314,.9474)	1789	.9756 (0.9624,.9853)
5	.5010 (-0.2485,.8693)	47	.8404 (0.7300,.9191)	333	.9415 (0.9339,.9491)	1936	.9766 (0.9630,.9861)
5	.5196 (-0.1919,.8715)	51	.8467 (0.7449,.9205)	341	.9423 (0.9348,.9499)	2095	.9776 (0.9636,.9869)
6	.5376 (-0.1371,.8736)	56	.8528 (0.7590,.9218)	369	.9446 (0.9375,.9524)	2228	.9783 (0.9641,.9875)
6	.5550 (-0.0843,.8757)	60	.8586 (0.7724,.9231)	399	.9468 (0.9402,.9549)	2267	.9785 (0.9642,.9877)
7	.5717 (-0.0333,.8777)	64	.8630 (0.7822,.9241)	432	.9489 (0.9427,.9574)	2453	.9793 (0.9648,.9884)
7	.5879 (0.0159,.8797)	65	.8642 (0.7851,.9243)	468	.9510 (0.9450,.9599)	2655	.9802 (0.9654,.9891)
8	.6035 (0.0632,.8817)	70	.8696 (0.7970,.9256)	475	.9514 (0.9454,.9603)	2873	.9810 (0.9660,.9897)
8	.6186 (0.1087,.8836)	76	.8748 (0.8084,.9268)	500	.9527 (0.9466,.9618)	3109	.9817 (0.9665,.9904)
9	.6331 (0.1525,.8855)	82	.8797 (0.8191,.9280)	506	.9530 (0.9469,.9622)	3364	.9825 (0.9671,.9909)
10	.6471 (0.1945,.8874)	84	.8812 (0.8224,.9284)	548	.9549 (0.9487,.9643)	3640	.9832 (0.9676,.9915)
11	.6606 (0.2347,.8892)	89	.8845 (0.8293,.9292)	593	.9567 (0.9504,.9664)	3939	.9839 (0.9682,.9920)
11	.6736 (0.2733,.8911)	96	.8891 (0.8389,.9304)	641	.9584 (0.9521,.9683)	4263	.9845 (0.9687,.9924)
12	.6861 (0.3103,.8928)	104	.8935 (0.8479,.9315)	693	.9601 (0.9536,.9701)	4613	.9851 (0.9692,.9929)
13	.6982 (0.3457,.8946)	113	.8978 (0.8563,.9326)	694	.9601 (0.9536,.9701)	4992	.9857 (0.9697,.9933)
15	.7099 (0.3795,.8963)	121	.9011 (0.8629,.9336)	751	.9617 (0.9545,.9718)	5401	.9863 (0.9702,.9937)
16	.7211 (0.4118,.8980)	122	.9018 (0.8643,.9338)	813	.9632 (0.9553,.9734)	5845	.9869 (0.9707,.9941)
17	.7319 (0.4426,.8997)	132	.9057 (0.8719,.9349)	879	.9647 (0.9561,.9749)	6325	.9874 (0.9712,.9944)
18	.7423 (0.4720,.9013)	143	.9095 (0.8790,.9359)	952	.9661 (0.9569,.9764)	6844	.9879 (0.9717,.9948)
20	.7523 (0.5001,.9030)	155	.9131 (0.8857,.9370)	1000	.9670 (0.9574,.9772)	7407	.9884 (0.9721,.9951)
22	.7619 (0.5268,.9046)	168	.9166 (0.8921,.9380)	1030	.9675 (0.9577,.9777)	8015	.9889 (0.9726,.9954)
23	.7712 (0.5522,.9061)	181	.9199 (0.8981,.9390)	1114	.9688 (0.9584,.9790)	8673	.9893 (0.9731,.9956)
25	.7801 (0.5764,.9077)	196	.9231 (0.9038,.9401)	1206	.9701 (0.9591,.9802)	9385	.9898 (0.9735,.9959)
27	.7887 (0.5994,.9092)	212	.9262 (0.9092,.9411)	1294	.9711 (0.9597,.9812)	10156	.9902 (0.9739,.9961)
30	.7970 (0.6212,.9107)	224	.9282 (0.9127,.9418)	1305	.9713 (0.9598,.9813)	9.8	.6471 (.1945,.8874)
32	.8050 (0.6420,.9122)	230	.9292 (0.9143,.9422)	1412	.9724 (0.9605,.9824)	121	.9011 (.8629,.9336)
35	.8126 (0.6617,.9136)	249	.9320 (0.9190,.9432)	1528	.9735 (0.9611,.9834)	468	.9510 (.9450,.9599)
37	.8200 (0.6802,.9150)	269	.9347 (0.9234,.9442)	1653	.9746 (0.9618,.9844)		

Table 5.6: Controlled VE with sensitivity analysis as functions of Day 29 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.6867 (.2040,.9214)	40	.8555 (.7474,.9302)	291	.9376 (.9279,.9454)	1785	.9734 (.9590,.9839)
4	.6941 (.2285,.9216)	44	.8598 (.7588,.9306)	315	.9400 (.9316,.9475)	1789	.9734 (.9590,.9839)
5	.7013 (.2527,.9218)	47	.8639 (.7697,.9311)	333	.9416 (.9340,.9492)	1936	.9743 (.9593,.9847)
5	.7084 (.2766,.9220)	51	.8680 (.7803,.9315)	341	.9423 (.9348,.9500)	2095	.9751 (.9597,.9855)
6	.7155 (.3003,.9222)	56	.8720 (.7905,.9320)	369	.9446 (.9375,.9524)	2228	.9757 (.9599,.9861)
6	.7224 (.3236,.9224)	60	.8759 (.8002,.9325)	399	.9468 (.9402,.9549)	2267	.9759 (.9600,.9862)
7	.7292 (.3466,.9227)	64	.8789 (.8075,.9329)	432	.9489 (.9427,.9574)	2453	.9767 (.9603,.9869)
7	.7359 (.3692,.9229)	65	.8797 (.8096,.9330)	468	.9509 (.9449,.9598)	2655	.9774 (.9606,.9876)
8	.7425 (.3915,.9231)	70	.8834 (.8186,.9335)	475	.9513 (.9454,.9603)	2873	.9781 (.9609,.9882)
8	.7489 (.4133,.9234)	76	.8871 (.8273,.9340)	500	.9525 (.9465,.9617)	3109	.9788 (.9611,.9888)
9	.7553 (.4347,.9236)	82	.8907 (.8356,.9346)	506	.9528 (.9468,.9621)	3364	.9795 (.9614,.9894)
10	.7615 (.4557,.9239)	84	.8917 (.8381,.9347)	548	.9546 (.9484,.9641)	3640	.9801 (.9617,.9899)
11	.7677 (.4761,.9242)	89	.8941 (.8435,.9351)	593	.9563 (.9500,.9661)	3939	.9807 (.9619,.9904)
11	.7737 (.4961,.9245)	96	.8975 (.8512,.9357)	641	.9580 (.9516,.9680)	4263	.9813 (.9621,.9909)
12	.7796 (.5156,.9247)	104	.9009 (.8584,.9362)	693	.9595 (.9529,.9697)	4613	.9818 (.9624,.9913)
13	.7854 (.5347,.9250)	113	.9041 (.8653,.9368)	694	.9595 (.9529,.9697)	4992	.9824 (.9626,.9917)
15	.7911 (.5532,.9253)	121	.9067 (.8707,.9373)	751	.9610 (.9537,.9713)	5401	.9829 (.9628,.9921)
16	.7966 (.5712,.9257)	122	.9073 (.8719,.9374)	813	.9624 (.9543,.9728)	5845	.9834 (.9630,.9925)
17	.8021 (.5887,.9260)	132	.9104 (.8782,.9381)	879	.9637 (.9549,.9742)	6325	.9839 (.9632,.9929)
18	.8075 (.6056,.9263)	143	.9134 (.8842,.9387)	952	.9650 (.9555,.9756)	6844	.9844 (.9634,.9932)
20	.8127 (.6221,.9267)	155	.9164 (.8900,.9393)	1000	.9658 (.9558,.9764)	7407	.9848 (.9636,.9935)
22	.8179 (.6380,.9270)	168	.9193 (.8956,.9400)	1030	.9662 (.9560,.9769)	8015	.9853 (.9638,.9939)
23	.8229 (.6535,.9274)	181	.9221 (.9009,.9407)	1114	.9674 (.9566,.9781)	8673	.9857 (.9639,.9942)
25	.8279 (.6684,.9277)	196	.9248 (.9060,.9414)	1206	.9685 (.9570,.9792)	9385	.9861 (.9641,.9944)
27	.8327 (.6828,.9281)	212	.9275 (.9108,.9422)	1294	.9695 (.9574,.9801)	10156	.9865 (.9642,.9947)
30	.8375 (.6968,.9285)	224	.9293 (.9140,.9427)	1305	.9696 (.9574,.9802)	9.8	.6471 (.1945,.8874)
32	.8421 (.7102,.9289)	230	.9301 (.9155,.9430)	1412	.9706 (.9578,.9812)	121	.9011 (.8629,.9336)
35	.8467 (.7232,.9293)	249	.9327 (.9199,.9438)	1528	.9716 (.9582,.9822)	468	.9510 (.9450,.9599)
37	.8511 (.7356,.9297)	269	.9352 (.9240,.9446)	1653	.9725 (.9586,.9831)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 192 as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.

Figure 5.9: Marginalized cumulative risk curves ($=s$).




(a) Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.



(b) Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.

Figure 5.10: Controlled VE curves (=s).



(a) Marginalized cumulative risk by Day 192 post Day 29 visit as functions of Day 29 markers above a threshold ($\geq s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 10 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 1.6$.

(b) Controlled VE as functions of Day 29 markers ($\geq s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 1.6$.

Figure 5.11: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 5.7: Marginalized cumulative risk by Day 192 as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
6.8	.0215 (.0052,.0503)	62	.0112 (.0050,.0189)	406	.0064 (.0050,.0080)	2470	.0037 (.0028,.0053)
7	.0210 (.0052,.0486)	67	.0110 (.0050,.0182)	439	.0063 (.0050,.0078)	2671	.0037 (.0027,.0053)
8	.0205 (.0052,.0470)	72	.0107 (.0050,.0175)	474	.0061 (.0050,.0075)	2890	.0036 (.0026,.0053)
9	.0201 (.0052,.0454)	78	.0105 (.0050,.0169)	500	.0060 (.0050,.0073)	2891	.0036 (.0026,.0053)
9	.0196 (.0052,.0439)	78	.0105 (.0050,.0169)	513	.0060 (.0050,.0072)	3126	.0035 (.0025,.0053)
10	.0192 (.0052,.0424)	84	.0102 (.0050,.0163)	555	.0058 (.0050,.0070)	3381	.0034 (.0024,.0053)
11	.0187 (.0052,.0409)	91	.0100 (.0050,.0158)	601	.0057 (.0050,.0067)	3658	.0033 (.0024,.0053)
12	.0183 (.0052,.0395)	99	.0098 (.0050,.0152)	603	.0057 (.0050,.0067)	3957	.0032 (.0023,.0053)
13	.0179 (.0051,.0382)	107	.0096 (.0050,.0147)	650	.0056 (.0049,.0065)	4073	.0032 (.0022,.0053)
14	.0175 (.0051,.0369)	115	.0093 (.0050,.0141)	703	.0054 (.0048,.0063)	4280	.0032 (.0022,.0053)
15	.0171 (.0051,.0356)	125	.0091 (.0050,.0136)	760	.0053 (.0046,.0061)	4630	.0031 (.0021,.0053)
16	.0167 (.0051,.0344)	125	.0091 (.0050,.0136)	822	.0052 (.0045,.0059)	5008	.0030 (.0020,.0053)
18	.0163 (.0051,.0332)	135	.0089 (.0050,.0132)	889	.0051 (.0043,.0058)	5417	.0030 (.0020,.0053)
19	.0159 (.0051,.0321)	146	.0087 (.0050,.0127)	912	.0050 (.0043,.0058)	5444	.0030 (.0020,.0053)
20	.0156 (.0051,.0310)	158	.0085 (.0050,.0122)	962	.0050 (.0042,.0057)	5860	.0029 (.0019,.0054)
22	.0152 (.0051,.0299)	171	.0083 (.0050,.0118)	1000	.0049 (.0041,.0057)	6339	.0028 (.0018,.0054)
24	.0149 (.0051,.0289)	185	.0081 (.0050,.0114)	1041	.0048 (.0040,.0056)	6857	.0028 (.0018,.0054)
26	.0145 (.0051,.0279)	188	.0081 (.0050,.0113)	1126	.0047 (.0039,.0055)	7417	.0027 (.0017,.0054)
28	.0142 (.0051,.0269)	200	.0079 (.0050,.0110)	1218	.0046 (.0038,.0055)	8023	.0026 (.0016,.0054)
30	.0139 (.0051,.0260)	216	.0077 (.0050,.0106)	1317	.0045 (.0037,.0054)	8679	.0026 (.0016,.0054)
33	.0135 (.0051,.0251)	234	.0076 (.0050,.0103)	1395	.0044 (.0036,.0054)	9388	.0025 (.0015,.0054)
36	.0132 (.0051,.0242)	253	.0074 (.0050,.0099)	1425	.0044 (.0035,.0054)	10155	.0024 (.0015,.0054)
38	.0129 (.0051,.0234)	274	.0072 (.0050,.0096)	1541	.0043 (.0034,.0053)	10985	.0024 (.0014,.0054)
42	.0126 (.0050,.0225)	296	.0070 (.0050,.0092)	1667	.0042 (.0033,.0053)	11883	.0023 (.0014,.0054)
45	.0123 (.0050,.0218)	320	.0069 (.0050,.0089)	1804	.0041 (.0032,.0053)	12854	.0023 (.0013,.0054)
49	.0121 (.0050,.0210)	347	.0067 (.0050,.0086)	1951	.0040 (.0031,.0053)	13904	.0022 (.0013,.0054)
53	.0118 (.0050,.0203)	375	.0066 (.0050,.0083)	2111	.0039 (.0030,.0053)	15040	.0022 (.0012,.0055)
57	.0115 (.0050,.0195)	376	.0066 (.0050,.0083)	2283	.0038 (.0029,.0053)	16269	.0021 (.0012,.0055)

Table 5.8: Controlled VE as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
6.8	.7892 (.5199,.9490)	67	.8922 (.8263,.9511)	474	.9399 (.9284,.9514)	2891	.9650 (.9494,.9742)
7	.7940 (.5359,.9491)	72	.8947 (.8324,.9512)	500	.9409 (.9300,.9514)	3126	.9658 (.9493,.9751)
8	.7986 (.5515,.9492)	78	.8971 (.8383,.9512)	513	.9413 (.9308,.9514)	3381	.9666 (.9493,.9760)
9	.8032 (.5666,.9493)	78	.8972 (.8384,.9512)	555	.9427 (.9332,.9516)	3658	.9674 (.9492,.9769)
9	.8077 (.5812,.9494)	84	.8995 (.8440,.9512)	601	.9440 (.9355,.9519)	3957	.9681 (.9492,.9777)
10	.8121 (.5953,.9495)	91	.9018 (.8495,.9513)	603	.9441 (.9356,.9519)	4073	.9684 (.9491,.9780)
11	.8163 (.6090,.9496)	99	.9041 (.8549,.9513)	650	.9453 (.9377,.9521)	4280	.9689 (.9491,.9785)
12	.8205 (.6223,.9497)	107	.9063 (.8600,.9513)	703	.9466 (.9398,.9530)	4630	.9696 (.9490,.9793)
13	.8246 (.6352,.9498)	115	.9085 (.8650,.9513)	760	.9478 (.9419,.9541)	5008	.9703 (.9490,.9801)
14	.8286 (.6476,.9499)	125	.9106 (.8698,.9514)	822	.9490 (.9437,.9555)	5417	.9710 (.9489,.9808)
15	.8325 (.6597,.9500)	125	.9106 (.8699,.9514)	889	.9502 (.9450,.9570)	5444	.9710 (.9489,.9808)
16	.8364 (.6713,.9501)	135	.9126 (.8744,.9514)	912	.9506 (.9453,.9574)	5860	.9717 (.9488,.9815)
18	.8401 (.6826,.9501)	146	.9147 (.8788,.9514)	962	.9514 (.9459,.9584)	6339	.9723 (.9488,.9821)
19	.8438 (.6935,.9502)	158	.9166 (.8830,.9514)	1000	.9519 (.9463,.9591)	6857	.9730 (.9487,.9828)
20	.8473 (.7041,.9503)	171	.9185 (.8870,.9514)	1041	.9525 (.9468,.9598)	7417	.9736 (.9486,.9834)
22	.8508 (.7143,.9504)	185	.9204 (.8909,.9514)	1126	.9536 (.9475,.9611)	8023	.9742 (.9486,.9840)
24	.8542 (.7242,.9504)	188	.9208 (.8917,.9514)	1218	.9547 (.9480,.9624)	8679	.9748 (.9485,.9846)
26	.8576 (.7337,.9505)	200	.9223 (.8947,.9514)	1317	.9557 (.9484,.9637)	9388	.9754 (.9484,.9852)
28	.8608 (.7430,.9506)	216	.9241 (.8983,.9514)	1395	.9565 (.9487,.9646)	10155	.9760 (.9483,.9857)
30	.8640 (.7519,.9506)	234	.9258 (.9018,.9514)	1425	.9567 (.9488,.9649)	10985	.9765 (.9483,.9862)
33	.8671 (.7605,.9507)	253	.9275 (.9052,.9514)	1541	.9578 (.9492,.9661)	11883	.9771 (.9482,.9867)
36	.8702 (.7689,.9508)	274	.9292 (.9085,.9514)	1667	.9587 (.9496,.9672)	12854	.9776 (.9481,.9872)
38	.8732 (.7770,.9508)	296	.9309 (.9116,.9514)	1804	.9597 (.9496,.9683)	13904	.9781 (.9480,.9877)
42	.8761 (.7847,.9509)	320	.9325 (.9147,.9514)	1951	.9606 (.9496,.9694)	15040	.9787 (.9479,.9881)
45	.8789 (.7923,.9509)	347	.9340 (.9176,.9514)	2111	.9615 (.9495,.9704)	16269	.9792 (.9478,.9885)
49	.8817 (.7996,.9510)	375	.9355 (.9204,.9514)	2283	.9624 (.9495,.9714)	(,)	
53	.8844 (.8066,.9510)	376	.9356 (.9206,.9514)	2470	.9633 (.9495,.9724)	84	.8995 (.8440,.9512)
57	.8871 (.8134,.9511)	406	.9370 (.9232,.9514)	2671	.9642 (.9494,.9733)	889	.9502 (.9450,.9570)
62	.8897 (.8199,.9511)	439	.9385 (.9258,.9514)	2890	.9650 (.9494,.9742)		

Table 5.9: Controlled VE with sensitivity analysis as functions of Day 29 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
6.8	.8673 (.6977,.9679)	67	.9081 (.8519,.9583)	474	.9404 (.9290,.9518)	2891	.9630 (.9464,.9727)
7	.8687 (.7044,.9676)	72	.9095 (.8559,.9580)	500	.9412 (.9305,.9517)	3126	.9636 (.9461,.9735)
8	.8702 (.7109,.9672)	78	.9108 (.8598,.9577)	513	.9416 (.9312,.9517)	3381	.9642 (.9457,.9743)
9	.8717 (.7174,.9669)	78	.9108 (.8599,.9577)	555	.9429 (.9335,.9518)	3658	.9648 (.9453,.9751)
9	.8731 (.7237,.9666)	84	.9121 (.8636,.9574)	601	.9441 (.9356,.9520)	3957	.9654 (.9448,.9758)
10	.8746 (.7300,.9663)	91	.9135 (.8674,.9570)	603	.9442 (.9357,.9520)	4073	.9656 (.9447,.9761)
11	.8760 (.7361,.9660)	99	.9148 (.8711,.9567)	650	.9454 (.9378,.9521)	4280	.9660 (.9444,.9765)
12	.8775 (.7422,.9657)	107	.9161 (.8747,.9564)	703	.9466 (.9399,.9530)	4630	.9666 (.9439,.9772)
13	.8789 (.7482,.9653)	115	.9174 (.8782,.9561)	760	.9478 (.9419,.9541)	5008	.9671 (.9434,.9779)
14	.8804 (.7540,.9650)	125	.9187 (.8816,.9558)	822	.9490 (.9437,.9554)	5417	.9676 (.9429,.9785)
15	.8818 (.7598,.9647)	125	.9188 (.8818,.9558)	889	.9502 (.9449,.9569)	5444	.9676 (.9429,.9786)
16	.8832 (.7655,.9644)	135	.9200 (.8850,.9555)	912	.9505 (.9452,.9574)	5860	.9681 (.9424,.9792)
18	.8847 (.7711,.9640)	146	.9213 (.8883,.9552)	962	.9513 (.9458,.9583)	6339	.9686 (.9419,.9797)
19	.8861 (.7765,.9637)	158	.9226 (.8915,.9549)	1000	.9518 (.9462,.9590)	6857	.9691 (.9413,.9803)
20	.8875 (.7819,.9634)	171	.9239 (.8945,.9546)	1041	.9523 (.9466,.9596)	7417	.9696 (.9408,.9809)
22	.8889 (.7872,.9630)	185	.9252 (.8975,.9543)	1126	.9533 (.9472,.9609)	8023	.9700 (.9402,.9814)
24	.8903 (.7924,.9627)	188	.9255 (.8981,.9543)	1218	.9543 (.9475,.9621)	8679	.9705 (.9396,.9819)
26	.8917 (.7975,.9624)	200	.9265 (.9004,.9541)	1317	.9552 (.9478,.9633)	9388	.9709 (.9389,.9824)
28	.8931 (.8025,.9620)	216	.9278 (.9033,.9538)	1395	.9559 (.9480,.9641)	10155	.9713 (.9383,.9829)
30	.8945 (.8075,.9617)	234	.9291 (.9061,.9536)	1425	.9561 (.9481,.9644)	10985	.9717 (.9376,.9834)
33	.8959 (.8123,.9614)	253	.9303 (.9089,.9533)	1541	.9570 (.9483,.9655)	11883	.9721 (.9370,.9838)
36	.8972 (.8171,.9610)	274	.9316 (.9116,.9531)	1667	.9579 (.9485,.9665)	12854	.9725 (.9363,.9843)
38	.8986 (.8217,.9607)	296	.9329 (.9142,.9528)	1804	.9587 (.9483,.9675)	13904	.9729 (.9356,.9847)
42	.9000 (.8263,.9604)	320	.9341 (.9168,.9526)	1951	.9594 (.9481,.9685)	15040	.9733 (.9348,.9851)
45	.9014 (.8308,.9600)	347	.9354 (.9193,.9525)	2111	.9602 (.9478,.9694)	16269	.9737 (.9341,.9855)
49	.9027 (.8352,.9597)	375	.9367 (.9218,.9523)	2283	.9609 (.9475,.9703)	(,)	
53	.9041 (.8395,.9593)	376	.9367 (.9219,.9523)	2470	.9616 (.9472,.9711)	84	.8995 (.8440,.9512)
57	.9054 (.8437,.9590)	406	.9379 (.9243,.9521)	2671	.9623 (.9468,.9719)	889	.9502 (.9450,.9570)
62	.9068 (.8479,.9587)	439	.9392 (.9266,.9520)	2890	.9630 (.9465,.9727)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 192 as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 2.4$.

Figure 5.12: Marginalized cumulative risk curves ($=s$).



(a) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 2.4$.



(b) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 2.4$.

Figure 5.13: Controlled VE curves ($=s$).




Figure 5.14: Marginalized cumulative risk curves and controlled VE curves ($>=s$).

Table 5.10: Marginalized cumulative risk by Day 192 as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
1.2	.0153 (.0070,.0395)	7	.0081 (.0058,.0123)	30	.0047 (.0036,.0056)	149	.0026 (.0012,.0043)
1	.0149 (.0069,.0378)	7	.0079 (.0058,.0117)	31	.0047 (.0035,.0056)	159	.0026 (.0012,.0043)
1	.0146 (.0069,.0363)	8	.0078 (.0058,.0114)	33	.0046 (.0034,.0055)	170	.0025 (.0011,.0043)
1	.0142 (.0069,.0348)	8	.0077 (.0058,.0112)	36	.0044 (.0032,.0054)	181	.0024 (.0011,.0042)
2	.0139 (.0068,.0333)	9	.0075 (.0057,.0107)	38	.0043 (.0031,.0054)	193	.0024 (.0010,.0042)
2	.0136 (.0068,.0319)	9	.0073 (.0057,.0103)	41	.0042 (.0030,.0053)	206	.0023 (.0010,.0042)
2	.0133 (.0067,.0306)	10	.0072 (.0056,.0098)	43	.0041 (.0029,.0052)	220	.0023 (.0009,.0042)
2	.0129 (.0067,.0293)	10	.0072 (.0056,.0098)	45	.0041 (.0028,.0052)	235	.0022 (.0009,.0041)
2	.0126 (.0066,.0281)	10	.0070 (.0056,.0094)	46	.0040 (.0027,.0052)	251	.0022 (.0008,.0041)
2	.0123 (.0066,.0269)	11	.0068 (.0056,.0090)	49	.0039 (.0026,.0051)	267	.0021 (.0008,.0041)
2	.0121 (.0065,.0257)	12	.0067 (.0055,.0086)	53	.0039 (.0025,.0051)	285	.0021 (.0008,.0040)
2	.0118 (.0065,.0247)	13	.0065 (.0055,.0083)	55	.0038 (.0024,.0050)	305	.0020 (.0007,.0040)
3	.0115 (.0064,.0236)	13	.0064 (.0054,.0079)	56	.0038 (.0024,.0050)	325	.0020 (.0007,.0040)
3	.0112 (.0064,.0226)	14	.0063 (.0054,.0077)	60	.0037 (.0023,.0050)	347	.0019 (.0007,.0039)
3	.0110 (.0064,.0216)	14	.0062 (.0054,.0076)	64	.0036 (.0022,.0049)	370	.0019 (.0006,.0039)
3	.0107 (.0063,.0207)	15	.0061 (.0053,.0074)	68	.0035 (.0021,.0049)	395	.0018 (.0006,.0039)
3	.0105 (.0063,.0198)	16	.0059 (.0051,.0071)	71	.0035 (.0020,.0048)	422	.0018 (.0006,.0039)
4	.0102 (.0062,.0190)	17	.0058 (.0050,.0068)	73	.0034 (.0020,.0048)	450	.0018 (.0006,.0038)
4	.0100 (.0062,.0182)	19	.0056 (.0048,.0065)	78	.0033 (.0019,.0048)	480	.0017 (.0005,.0038)
4	.0097 (.0062,.0174)	19	.0056 (.0048,.0065)	83	.0033 (.0018,.0047)	500	.0017 (.0005,.0038)
4	.0095 (.0061,.0167)	20	.0055 (.0047,.0063)	89	.0032 (.0017,.0047)	512	.0017 (.0005,.0038)
5	.0093 (.0061,.0160)	21	.0054 (.0045,.0061)	94	.0031 (.0017,.0046)	547	.0016 (.0005,.0038)
5	.0091 (.0060,.0153)	23	.0053 (.0043,.0060)	101	.0030 (.0016,.0046)	584	.0016 (.0005,.0037)
5	.0089 (.0060,.0146)	24	.0051 (.0041,.0059)	108	.0030 (.0015,.0045)	623	.0016 (.0004,.0037)
6	.0087 (.0059,.0140)	24	.0051 (.0041,.0059)	115	.0029 (.0015,.0045)	665	.0015 (.0004,.0037)
6	.0085 (.0059,.0136)	26	.0050 (.0040,.0058)	123	.0028 (.0014,.0044)	709	.0015 (.0004,.0036)
6	.0085 (.0059,.0134)	27	.0049 (.0038,.0057)	131	.0028 (.0013,.0044)	757	.0014 (.0004,.0036)
7	.0083 (.0059,.0128)	29	.0048 (.0037,.0057)	140	.0027 (.0013,.0044)	1000	.0013 (.0003,.0035)

Table 5.11: Controlled VE as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
1.2	.8503 (.6195,.9322)	7	.9228 (.8870,.9440)	33	.9553 (.9473,.9663)	181	.9760 (.9595,.9893)
1	.8538 (.6353,.9327)	8	.9239 (.8902,.9442)	36	.9564 (.9480,.9676)	193	.9765 (.9597,.9898)
1	.8572 (.6504,.9332)	8	.9246 (.8919,.9443)	38	.9574 (.9487,.9689)	206	.9771 (.9600,.9902)
1	.8605 (.6650,.9336)	9	.9263 (.8966,.9447)	41	.9584 (.9494,.9702)	220	.9776 (.9603,.9907)
2	.8637 (.6790,.9341)	9	.9281 (.9010,.9451)	43	.9594 (.9501,.9713)	235	.9782 (.9606,.9911)
2	.8669 (.6925,.9345)	10	.9298 (.9053,.9455)	45	.9601 (.9505,.9722)	251	.9787 (.9609,.9915)
2	.8700 (.7054,.9349)	10	.9298 (.9055,.9455)	46	.9603 (.9507,.9725)	267	.9792 (.9612,.9918)
2	.8730 (.7177,.9354)	10	.9314 (.9094,.9458)	49	.9613 (.9513,.9736)	285	.9797 (.9615,.9922)
2	.8760 (.7296,.9358)	11	.9330 (.9133,.9462)	53	.9622 (.9517,.9747)	305	.9802 (.9617,.9925)
2	.8789 (.7410,.9363)	12	.9346 (.9171,.9466)	55	.9628 (.9521,.9755)	325	.9806 (.9620,.9929)
2	.8817 (.7520,.9367)	13	.9361 (.9206,.9469)	56	.9631 (.9522,.9758)	347	.9811 (.9623,.9932)
2	.8845 (.7625,.9371)	13	.9376 (.9240,.9473)	60	.9639 (.9527,.9769)	370	.9815 (.9626,.9935)
3	.8872 (.7725,.9375)	14	.9386 (.9259,.9475)	64	.9648 (.9532,.9779)	395	.9820 (.9628,.9938)
3	.8898 (.7822,.9380)	14	.9391 (.9269,.9476)	68	.9656 (.9537,.9789)	422	.9824 (.9631,.9941)
3	.8924 (.7914,.9384)	15	.9405 (.9297,.9481)	71	.9662 (.9540,.9795)	450	.9828 (.9633,.9943)
3	.8949 (.8003,.9388)	16	.9419 (.9323,.9491)	73	.9664 (.9541,.9798)	480	.9832 (.9636,.9946)
3	.8974 (.8088,.9392)	17	.9433 (.9349,.9506)	78	.9672 (.9546,.9807)	500	.9835 (.9637,.9947)
4	.8998 (.8170,.9396)	19	.9446 (.9374,.9521)	83	.9680 (.9551,.9816)	512	.9836 (.9638,.9948)
4	.9021 (.8248,.9400)	19	.9447 (.9375,.9522)	89	.9688 (.9555,.9824)	547	.9840 (.9641,.9950)
4	.9044 (.8323,.9404)	20	.9459 (.9394,.9536)	94	.9695 (.9560,.9832)	584	.9844 (.9643,.9953)
4	.9066 (.8395,.9408)	21	.9472 (.9408,.9552)	101	.9702 (.9564,.9839)	623	.9847 (.9646,.9955)
5	.9088 (.8463,.9412)	23	.9484 (.9421,.9570)	108	.9709 (.9569,.9846)	665	.9851 (.9648,.9957)
5	.9110 (.8529,.9416)	24	.9497 (.9431,.9587)	115	.9716 (.9573,.9853)	709	.9855 (.9650,.9959)
5	.9130 (.8592,.9420)	24	.9497 (.9431,.9587)	123	.9723 (.9576,.9860)	757	.9858 (.9653,.9960)
6	.9151 (.8653,.9424)	26	.9508 (.9442,.9603)	131	.9729 (.9579,.9866)	1000	.9872 (.9662,.9968)
6	.9164 (.8691,.9427)	27	.9520 (.9452,.9619)	140	.9736 (.9583,.9872)	(,)	
6	.9171 (.8711,.9428)	29	.9531 (.9459,.9634)	149	.9742 (.9586,.9877)	4	.8998 (.8170,.9396)
7	.9190 (.8766,.9432)	30	.9537 (.9463,.9642)	159	.9748 (.9589,.9883)	24	.9497 (.9431,.9587)
7	.9209 (.8819,.9436)	31	.9542 (.9466,.9649)	170	.9754 (.9592,.9888)		

Table 5.12: Controlled VE with sensitivity analysis as functions of Day 29 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
1.2	.9111 (.7740,.9597)	7	.9301 (.8978,.9493)	33	.9543 (.9462,.9655)	181	.9665 (.9434,.9851)
1	.9116 (.7794,.9593)	8	.9307 (.8999,.9492)	36	.9551 (.9465,.9667)	193	.9667 (.9429,.9855)
1	.9121 (.7848,.9589)	8	.9310 (.9011,.9491)	38	.9558 (.9469,.9678)	206	.9670 (.9424,.9859)
1	.9126 (.7902,.9584)	9	.9319 (.9044,.9489)	41	.9566 (.9472,.9688)	220	.9672 (.9418,.9863)
2	.9131 (.7954,.9580)	9	.9329 (.9076,.9488)	43	.9572 (.9474,.9698)	235	.9675 (.9413,.9867)
2	.9137 (.8006,.9575)	10	.9339 (.9108,.9486)	45	.9577 (.9476,.9705)	251	.9677 (.9407,.9871)
2	.9143 (.8056,.9571)	10	.9339 (.9110,.9486)	46	.9579 (.9477,.9708)	267	.9679 (.9401,.9874)
2	.9148 (.8106,.9566)	10	.9348 (.9139,.9485)	49	.9585 (.9478,.9717)	285	.9681 (.9395,.9878)
2	.9154 (.8156,.9562)	11	.9359 (.9170,.9485)	53	.9591 (.9478,.9726)	305	.9683 (.9389,.9881)
2	.9160 (.8204,.9558)	12	.9369 (.9200,.9484)	55	.9595 (.9478,.9733)	325	.9685 (.9383,.9884)
2	.9166 (.8251,.9554)	13	.9379 (.9229,.9484)	56	.9596 (.9478,.9735)	347	.9687 (.9376,.9887)
2	.9172 (.8298,.9549)	13	.9390 (.9257,.9484)	60	.9602 (.9478,.9745)	370	.9689 (.9370,.9890)
3	.9179 (.8344,.9545)	14	.9397 (.9273,.9485)	64	.9607 (.9477,.9753)	395	.9691 (.9363,.9893)
3	.9185 (.8389,.9541)	14	.9401 (.9281,.9485)	68	.9611 (.9476,.9761)	422	.9693 (.9356,.9896)
3	.9192 (.8434,.9537)	15	.9412 (.9305,.9488)	71	.9614 (.9476,.9767)	450	.9694 (.9348,.9899)
3	.9199 (.8478,.9533)	16	.9424 (.9329,.9495)	73	.9616 (.9476,.9769)	480	.9696 (.9341,.9902)
3	.9206 (.8520,.9530)	17	.9435 (.9352,.9508)	78	.9621 (.9474,.9777)	500	.9697 (.9336,.9903)
4	.9213 (.8562,.9526)	19	.9447 (.9375,.9522)	83	.9625 (.9473,.9784)	512	.9698 (.9333,.9904)
4	.9220 (.8604,.9522)	19	.9448 (.9376,.9523)	89	.9629 (.9472,.9791)	547	.9699 (.9325,.9907)
4	.9227 (.8644,.9519)	20	.9460 (.9394,.9536)	94	.9633 (.9470,.9797)	584	.9701 (.9317,.9909)
4	.9235 (.8684,.9515)	21	.9472 (.9408,.9552)	101	.9637 (.9468,.9804)	623	.9702 (.9308,.9911)
5	.9242 (.8723,.9512)	23	.9484 (.9420,.9569)	108	.9640 (.9466,.9810)	665	.9704 (.9300,.9914)
5	.9250 (.8762,.9509)	24	.9496 (.9430,.9586)	115	.9644 (.9464,.9816)	709	.9705 (.9291,.9916)
5	.9258 (.8800,.9506)	24	.9496 (.9430,.9586)	123	.9647 (.9461,.9821)	757	.9707 (.9282,.9918)
6	.9267 (.8837,.9503)	26	.9506 (.9439,.9602)	131	.9650 (.9457,.9827)	1000	.9712 (.9242,.9927)
6	.9272 (.8860,.9501)	27	.9516 (.9447,.9616)	140	.9653 (.9452,.9832)	(,)	
6	.9275 (.8873,.9500)	29	.9526 (.9453,.9630)	149	.9656 (.9448,.9837)	4	.8998 (.8170,.9396)
7	.9283 (.8908,.9497)	30	.9530 (.9455,.9637)	159	.9659 (.9444,.9842)	24	.9497 (.9431,.9587)
7	.9292 (.8943,.9495)	31	.9535 (.9457,.9643)	170	.9662 (.9439,.9846)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 15.

Figure 5.15: Marginalized cumulative risk curves (=s).



(a) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 15$.



(b) Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 15$.

Figure 5.16: Controlled VE curves ($=s$).




Figure 5.17: Marginalized cumulative risk curves and controlled VE curves ($>=s$).

Table 5.13: Marginalized cumulative risk by Day 192 as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
7.5	.0096 (.0067,.0160)	22	.0059 (.0051,.0072)	61	.0037 (.0028,.0044)	179	.0023 (.0013,.0036)
8	.0096 (.0067,.0160)	22	.0059 (.0051,.0072)	63	.0037 (.0028,.0044)	187	.0023 (.0013,.0036)
8	.0096 (.0067,.0160)	23	.0058 (.0050,.0069)	64	.0037 (.0028,.0044)	195	.0022 (.0012,.0035)
8	.0094 (.0066,.0155)	24	.0057 (.0049,.0067)	67	.0036 (.0027,.0044)	204	.0022 (.0012,.0035)
8	.0092 (.0066,.0150)	25	.0056 (.0048,.0065)	70	.0035 (.0026,.0043)	213	.0021 (.0012,.0035)
9	.0090 (.0065,.0145)	26	.0055 (.0047,.0063)	73	.0035 (.0025,.0043)	222	.0021 (.0011,.0035)
9	.0089 (.0065,.0140)	27	.0054 (.0046,.0061)	74	.0034 (.0025,.0043)	232	.0021 (.0011,.0034)
9	.0087 (.0064,.0136)	28	.0054 (.0045,.0061)	76	.0034 (.0025,.0043)	242	.0020 (.0011,.0034)
10	.0085 (.0064,.0131)	28	.0053 (.0045,.0059)	79	.0033 (.0024,.0042)	253	.0020 (.0010,.0034)
10	.0084 (.0063,.0127)	30	.0052 (.0044,.0058)	83	.0033 (.0023,.0042)	264	.0019 (.0010,.0033)
11	.0082 (.0063,.0123)	31	.0051 (.0043,.0056)	87	.0032 (.0023,.0041)	275	.0019 (.0010,.0033)
11	.0081 (.0062,.0119)	32	.0050 (.0042,.0055)	90	.0031 (.0022,.0041)	288	.0019 (.0009,.0033)
12	.0079 (.0062,.0115)	34	.0049 (.0041,.0054)	90	.0031 (.0022,.0041)	300	.0018 (.0009,.0033)
12	.0078 (.0061,.0112)	35	.0048 (.0040,.0053)	94	.0031 (.0021,.0041)	313	.0018 (.0009,.0032)
13	.0076 (.0060,.0108)	35	.0048 (.0040,.0053)	98	.0030 (.0021,.0040)	327	.0018 (.0008,.0032)
13	.0075 (.0060,.0105)	37	.0047 (.0039,.0052)	103	.0030 (.0020,.0040)	341	.0017 (.0008,.0032)
14	.0073 (.0059,.0102)	38	.0046 (.0038,.0051)	107	.0029 (.0019,.0040)	356	.0017 (.0008,.0032)
14	.0072 (.0058,.0098)	40	.0045 (.0037,.0050)	112	.0028 (.0019,.0039)	372	.0017 (.0008,.0031)
15	.0070 (.0058,.0095)	42	.0044 (.0036,.0049)	117	.0028 (.0018,.0039)	388	.0016 (.0007,.0031)
15	.0070 (.0057,.0094)	43	.0044 (.0036,.0049)	122	.0027 (.0018,.0039)	405	.0016 (.0007,.0031)
16	.0069 (.0057,.0092)	44	.0044 (.0035,.0049)	127	.0027 (.0017,.0039)	423	.0016 (.0007,.0031)
16	.0068 (.0056,.0089)	45	.0043 (.0034,.0048)	133	.0026 (.0017,.0038)	441	.0015 (.0007,.0030)
17	.0067 (.0056,.0087)	47	.0042 (.0033,.0047)	139	.0026 (.0016,.0038)	461	.0015 (.0006,.0030)
18	.0065 (.0055,.0084)	50	.0041 (.0032,.0046)	145	.0025 (.0016,.0038)	481	.0015 (.0006,.0030)
18	.0064 (.0055,.0081)	52	.0040 (.0032,.0046)	151	.0025 (.0015,.0037)	500	.0015 (.0006,.0030)
19	.0063 (.0054,.0079)	54	.0040 (.0031,.0045)	158	.0024 (.0015,.0037)	502	.0014 (.0006,.0030)
20	.0062 (.0053,.0076)	56	.0039 (.0030,.0045)	165	.0024 (.0014,.0037)	524	.0014 (.0006,.0029)
21	.0060 (.0052,.0074)	59	.0038 (.0029,.0045)	172	.0023 (.0014,.0036)	1000	.0011 (.0003,.0026)

Table 5.14: Controlled VE as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
7.5	.9060 (.8461,.9332)	22	.9418 (.9315,.9493)	64	.9641 (.9561,.9722)	204	.9787 (.9649,.9883)
8	.9060 (.8461,.9332)	23	.9429 (.9336,.9502)	67	.9648 (.9565,.9730)	213	.9791 (.9652,.9887)
8	.9060 (.8461,.9332)	24	.9440 (.9356,.9512)	70	.9654 (.9568,.9738)	222	.9795 (.9655,.9891)
8	.9078 (.8511,.9338)	25	.9451 (.9376,.9522)	73	.9661 (.9572,.9746)	232	.9799 (.9657,.9895)
8	.9095 (.8560,.9344)	26	.9461 (.9395,.9532)	74	.9663 (.9573,.9748)	242	.9803 (.9660,.9898)
9	.9112 (.8607,.9349)	27	.9472 (.9412,.9542)	76	.9667 (.9575,.9754)	253	.9806 (.9663,.9901)
9	.9129 (.8653,.9355)	28	.9475 (.9415,.9545)	79	.9674 (.9579,.9761)	264	.9810 (.9666,.9905)
9	.9146 (.8697,.9360)	28	.9482 (.9425,.9552)	83	.9680 (.9582,.9768)	275	.9814 (.9668,.9908)
10	.9162 (.8739,.9365)	30	.9492 (.9438,.9563)	87	.9686 (.9586,.9775)	288	.9817 (.9671,.9911)
10	.9178 (.8781,.9371)	31	.9501 (.9450,.9573)	90	.9692 (.9589,.9782)	300	.9821 (.9674,.9914)
11	.9193 (.8821,.9376)	32	.9511 (.9461,.9583)	90	.9692 (.9589,.9782)	313	.9824 (.9676,.9917)
11	.9209 (.8859,.9381)	34	.9520 (.9472,.9593)	94	.9698 (.9593,.9789)	327	.9828 (.9679,.9919)
12	.9224 (.8897,.9386)	35	.9527 (.9479,.9600)	98	.9704 (.9596,.9795)	341	.9831 (.9682,.9922)
12	.9239 (.8933,.9392)	35	.9529 (.9481,.9602)	103	.9710 (.9599,.9801)	356	.9834 (.9684,.9925)
13	.9253 (.8968,.9397)	37	.9538 (.9490,.9611)	107	.9715 (.9603,.9807)	372	.9837 (.9687,.9927)
13	.9267 (.9001,.9403)	38	.9547 (.9499,.9620)	112	.9721 (.9606,.9814)	388	.9840 (.9689,.9930)
14	.9281 (.9032,.9409)	40	.9556 (.9507,.9629)	117	.9726 (.9609,.9820)	405	.9844 (.9692,.9932)
14	.9295 (.9062,.9416)	42	.9564 (.9515,.9638)	122	.9731 (.9612,.9826)	423	.9847 (.9695,.9934)
15	.9308 (.9091,.9422)	43	.9570 (.9520,.9643)	127	.9736 (.9615,.9831)	441	.9849 (.9697,.9936)
15	.9315 (.9105,.9425)	44	.9573 (.9523,.9646)	133	.9741 (.9619,.9837)	461	.9852 (.9699,.9938)
16	.9322 (.9119,.9428)	45	.9581 (.9530,.9654)	139	.9746 (.9622,.9842)	481	.9855 (.9702,.9940)
16	.9334 (.9147,.9434)	47	.9589 (.9534,.9663)	145	.9751 (.9625,.9848)	500	.9858 (.9704,.9942)
17	.9347 (.9173,.9440)	50	.9597 (.9539,.9672)	151	.9756 (.9628,.9853)	502	.9858 (.9704,.9942)
18	.9360 (.9199,.9446)	52	.9604 (.9542,.9681)	158	.9761 (.9631,.9857)	524	.9861 (.9707,.9944)
18	.9372 (.9223,.9454)	54	.9612 (.9546,.9690)	165	.9765 (.9634,.9862)	1000	.9896 (.9741,.9966)
19	.9384 (.9247,.9464)	56	.9619 (.9550,.9698)	172	.9770 (.9637,.9867)	(,)	
20	.9395 (.9270,.9474)	59	.9627 (.9554,.9706)	179	.9774 (.9640,.9871)	8	.9060 (.8461,.9332)
21	.9407 (.9293,.9484)	61	.9634 (.9557,.9714)	187	.9778 (.9643,.9875)	31	.9501 (.9450,.9573)
22	.9417 (.9312,.9492)	63	.9637 (.9559,.9718)	195	.9783 (.9646,.9879)		

Table 5.15: Controlled VE with sensitivity analysis as functions of Day 29 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
7.5	.9158 (.8622,.9402)	22	.9421 (.9317,.9495)	64	.9621 (.9537,.9707)	204	.9730 (.9556,.9853)
8	.9158 (.8622,.9402)	23	.9431 (.9337,.9504)	67	.9626 (.9538,.9713)	213	.9733 (.9556,.9856)
8	.9158 (.8622,.9402)	24	.9441 (.9357,.9513)	70	.9632 (.9540,.9721)	222	.9736 (.9556,.9860)
8	.9169 (.8658,.9403)	25	.9451 (.9376,.9522)	73	.9637 (.9541,.9728)	232	.9739 (.9556,.9863)
8	.9179 (.8694,.9405)	26	.9462 (.9395,.9532)	74	.9638 (.9541,.9730)	242	.9742 (.9556,.9867)
9	.9190 (.8729,.9406)	27	.9472 (.9412,.9542)	76	.9642 (.9542,.9734)	253	.9745 (.9556,.9870)
9	.9201 (.8764,.9408)	28	.9475 (.9415,.9545)	79	.9647 (.9544,.9741)	264	.9747 (.9555,.9873)
9	.9212 (.8797,.9409)	28	.9482 (.9425,.9552)	83	.9651 (.9545,.9747)	275	.9750 (.9555,.9876)
10	.9222 (.8830,.9411)	30	.9491 (.9437,.9563)	87	.9656 (.9546,.9754)	288	.9753 (.9555,.9879)
10	.9233 (.8862,.9413)	31	.9501 (.9449,.9572)	90	.9661 (.9547,.9760)	300	.9755 (.9555,.9882)
11	.9243 (.8894,.9415)	32	.9510 (.9460,.9582)	90	.9661 (.9547,.9760)	313	.9758 (.9554,.9885)
11	.9254 (.8924,.9417)	34	.9518 (.9469,.9591)	94	.9665 (.9548,.9765)	327	.9760 (.9554,.9888)
12	.9265 (.8955,.9419)	35	.9525 (.9476,.9598)	98	.9669 (.9549,.9771)	341	.9763 (.9554,.9891)
12	.9275 (.8984,.9421)	35	.9527 (.9478,.9600)	103	.9674 (.9550,.9776)	356	.9765 (.9553,.9893)
13	.9286 (.9013,.9423)	37	.9535 (.9486,.9608)	107	.9678 (.9550,.9782)	372	.9768 (.9553,.9896)
13	.9296 (.9040,.9426)	38	.9543 (.9494,.9617)	112	.9682 (.9551,.9788)	388	.9770 (.9552,.9898)
14	.9307 (.9066,.9430)	40	.9550 (.9501,.9625)	117	.9686 (.9552,.9793)	405	.9772 (.9552,.9901)
14	.9317 (.9092,.9434)	42	.9558 (.9508,.9632)	122	.9690 (.9552,.9799)	423	.9775 (.9551,.9903)
15	.9328 (.9116,.9438)	43	.9562 (.9512,.9637)	127	.9693 (.9553,.9804)	441	.9777 (.9551,.9905)
15	.9333 (.9128,.9440)	44	.9565 (.9515,.9640)	133	.9697 (.9553,.9809)	461	.9779 (.9550,.9908)
16	.9338 (.9141,.9442)	45	.9572 (.9520,.9647)	139	.9701 (.9554,.9814)	481	.9781 (.9549,.9910)
16	.9348 (.9164,.9446)	47	.9579 (.9523,.9654)	145	.9704 (.9554,.9819)	500	.9783 (.9549,.9912)
17	.9359 (.9188,.9450)	50	.9585 (.9525,.9663)	151	.9708 (.9555,.9824)	502	.9783 (.9549,.9912)
18	.9369 (.9210,.9454)	52	.9592 (.9527,.9670)	158	.9711 (.9555,.9828)	524	.9785 (.9548,.9914)
18	.9379 (.9233,.9461)	54	.9598 (.9530,.9678)	165	.9715 (.9555,.9833)	1000	.9813 (.9535,.9940)
19	.9390 (.9255,.9470)	56	.9604 (.9531,.9686)	172	.9718 (.9555,.9837)	(,)	
20	.9400 (.9276,.9478)	59	.9610 (.9533,.9693)	179	.9721 (.9556,.9841)	8	.9060 (.8461,.9332)
21	.9410 (.9297,.9487)	61	.9615 (.9535,.9700)	187	.9724 (.9556,.9845)	31	.9501 (.9450,.9573)
22	.9419 (.9315,.9494)	63	.9618 (.9536,.9703)	195	.9727 (.9556,.9849)		

Chapter 6

Day D57 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

6.1 Hazard ratios

Table 6.1: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

MockCOVE Immunologic Marker	No. cases / No. at-risk**	HR per 10-fold incr. Pt. Est.	P-value 95% CI (2-sided)	q-value ***	FWER
Anti Spike IgG (BAU/ml)	52/11,117	0.20	(0.11-0.36)	<0.001	<0.001 <0.001
Anti RBD IgG (BAU/ml)	52/11,117	0.43	(0.25-0.74)	0.003	<0.001 <0.001
Pseudovirus-nAb cID50	52/11,117	0.32	(0.17-0.60)	<0.001	<0.001 <0.001
Pseudovirus-nAb cID80	52/11,117	0.34	(0.18-0.63)	<0.001	<0.001 <0.001

*Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. Maximum failure event time 164 days.

**No. at-risk = estimated number in the population for analysis, i.e. baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint or infected through 6 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoint.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).

Table 6.2: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

MockCOVE Immunologic Marker	Tertile	No. cases / No. at-risk**	Attack rate	Pt. Est.	Haz. Ratio 95% CI	P-value (2-sided)	Overall P- value***	Overall q- value †	Overall FWER
Anti Spike IgG (BAU/ml)	Lower	27/4,235	0.0064	1	N/A	N/A	<0.001	<0.001	<0.001
	Middle	18/4,243	0.0042	0.30	(0.16-0.58)	<0.001			
	Upper	7/2,638	0.0027	0.08	(0.03-0.21)	<0.001			
Anti RBD IgG (BAU/ml)	Lower	24/4,242	0.0057	1	N/A	N/A	0.003	<0.001	<0.001
	Middle	14/4,209	0.0033	0.32	(0.15-0.70)	0.004			
	Upper	14/2,666	0.0053	0.29	(0.13-0.63)	0.002			
Pseudovirus-nAb cID50	Lower	18/3,697	0.0049	1	N/A	N/A	0.035	<0.001	<0.001
	Middle	20/3,701	0.0054	0.80	(0.39-1.64)	0.546			
	Upper	14/3,719	0.0038	0.37	(0.16-0.82)	0.015			
Pseudovirus-nAb cID80	Lower	22/3,724	0.0059	1	N/A	N/A	0.009	<0.001	<0.001
	Middle	20/3,707	0.0054	0.66	(0.34-1.26)	0.206			
	Upper	10/3,687	0.0027	0.29	(0.13-0.64)	0.002			
Placebo		953/11,217	0.0850						

*Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. Maximum failure event time 164 days. Cutpoints: Anti Spike IgG (BAU/ml) [3.34, 4.01], Anti RBD IgG (BAU/ml) [3.48, 4.21], Pseudovirus-nAb cID50 [2.37, 2.86], Pseudovirus-nAb cID80 [2.58, 2.96], all on the log10 scale.

**No. at-risk = estimated number in the population for analysis, i.e. baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint or infected through 6 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoint.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).




Figure 6.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 57




Figure 6.2: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 57




Figure 6.3: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.




Figure 6.4: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

MOCT

PsV Neutralization 80% Titer: Day 57




Figure 6.5: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.


6.2 Marginalized risk and controlled vaccine efficacy plots

Table 6.3: Analysis of Day 57 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.


	marginalized risk		controlled risk		e(0,1) ²
	ratio $RR_M(0, 1)$	Point Est. 95% CI	ratio $RR_C(0, 1)$ ¹	Point Est. 95% CI	
Anti Spike IgG (BAU/ml)	0.09	0.04–0.19	0.11	0.06–0.25	22.8
Anti RBD IgG (BAU/ml)	0.29	0.11–0.46	0.39	0.15–0.62	6.4
Pseudovirus-nAb cID50	0.37	0.24–0.54	0.49	0.32–0.72	4.9
Pseudovirus-nAb cID80	0.29	0.14–0.66	0.39	0.18–0.88	6.3

¹Conservative (upper bound) estimate assuming unmeasured confounding at level $RR_{UD}(0, 1) = RR_{EU}(0, 1) = 2$ and thus $B(0, 1) = 4/3$.

²E-values are computed for upper tertile ($s = 1$) vs. lower tertile ($s = 0$) biomarker subgroups after controlling for MinorityInd + HighRiskInd + riskscore; UL = upper limit.



(a) Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.



(b) Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lsd = 0.3.

Figure 6.6: Marginalized cumulative risk curves ($=s$).




Figure 6.7: Controlled VE curves ($=s$).




Figure 6.8: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 6.4: Marginalized cumulative risk by Day 164 as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
20.7	.1334 (.0442,.3655)	119	.0477 (.0212,.1432)	647	.0157 (.0101,.0349)	2905	.0056 (.0045,.0077)
22	.1290 (.0431,.3558)	127	.0459 (.0206,.1373)	653	.0156 (.0100,.0346)	2957	.0055 (.0045,.0076)
23	.1248 (.0420,.3462)	135	.0441 (.0201,.1315)	689	.0150 (.0098,.0329)	3092	.0054 (.0043,.0072)
25	.1206 (.0409,.3367)	144	.0423 (.0195,.1258)	733	.0144 (.0095,.0309)	3292	.0051 (.0041,.0068)
27	.1166 (.0399,.3273)	153	.0407 (.0190,.1203)	780	.0138 (.0092,.0291)	3505	.0049 (.0040,.0064)
28	.1127 (.0389,.3181)	163	.0391 (.0185,.1149)	831	.0132 (.0090,.0273)	3731	.0047 (.0038,.0060)
30	.1088 (.0379,.3090)	174	.0375 (.0180,.1097)	884	.0127 (.0087,.0257)	3972	.0045 (.0036,.0056)
32	.1051 (.0369,.3000)	185	.0360 (.0175,.1046)	942	.0121 (.0085,.0241)	4229	.0043 (.0035,.0052)
34	.1014 (.0360,.2912)	197	.0346 (.0171,.0997)	960	.0120 (.0084,.0237)	4502	.0041 (.0033,.0049)
36	.0979 (.0350,.2825)	210	.0332 (.0166,.0950)	1000	.0117 (.0083,.0227)	4553	.0041 (.0033,.0049)
39	.0945 (.0341,.2740)	223	.0319 (.0162,.0904)	1002	.0116 (.0082,.0227)	4792	.0040 (.0032,.0046)
41	.0911 (.0333,.2655)	238	.0306 (.0157,.0859)	1067	.0111 (.0080,.0213)	5102	.0038 (.0030,.0043)
44	.0879 (.0324,.2573)	253	.0294 (.0153,.0816)	1136	.0107 (.0078,.0200)	5431	.0036 (.0029,.0042)
47	.0847 (.0316,.2491)	269	.0282 (.0149,.0775)	1209	.0102 (.0076,.0188)	5782	.0035 (.0028,.0041)
50	.0817 (.0307,.2411)	287	.0270 (.0145,.0735)	1288	.0098 (.0074,.0176)	6156	.0033 (.0027,.0040)
53	.0787 (.0299,.2332)	305	.0259 (.0141,.0697)	1297	.0098 (.0073,.0175)	6553	.0032 (.0025,.0039)
56	.0758 (.0291,.2255)	325	.0249 (.0137,.0660)	1371	.0094 (.0072,.0166)	6937	.0031 (.0024,.0038)
60	.0730 (.0284,.2179)	346	.0239 (.0134,.0625)	1459	.0090 (.0070,.0155)	6976	.0031 (.0024,.0038)
64	.0703 (.0276,.2104)	368	.0229 (.0130,.0591)	1553	.0086 (.0068,.0146)	7427	.0029 (.0023,.0037)
68	.0677 (.0269,.2031)	392	.0219 (.0126,.0559)	1654	.0083 (.0066,.0137)	7907	.0028 (.0022,.0036)
72	.0652 (.0262,.1959)	417	.0210 (.0123,.0528)	1761	.0079 (.0063,.0128)	8417	.0027 (.0021,.0035)
77	.0627 (.0255,.1888)	444	.0202 (.0119,.0498)	1874	.0076 (.0061,.0121)	8961	.0026 (.0020,.0034)
82	.0604 (.0249,.1819)	473	.0194 (.0116,.0470)	1995	.0073 (.0058,.0113)	9540	.0025 (.0019,.0033)
87	.0581 (.0242,.1751)	500	.0186 (.0113,.0447)	2124	.0070 (.0056,.0106)	10145	.0024 (.0018,.0032)
93	.0558 (.0236,.1685)	504	.0186 (.0113,.0444)	2261	.0067 (.0054,.0100)	10156	.0024 (.0018,.0032)
99	.0537 (.0229,.1619)	536	.0178 (.0109,.0418)	2408	.0064 (.0051,.0093)	10156	.0024 (.0018,.0032)
105	.0516 (.0223,.1556)	571	.0171 (.0106,.0394)	2563	.0061 (.0049,.0088)	10156	.0024 (.0018,.0032)
112	.0496 (.0217,.1493)	608	.0163 (.0103,.0371)	2729	.0059 (.0047,.0082)	10156	.0024 (.0018,.0032)

Table 6.5: Controlled VE as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
20.7	-0.4851 (-2.8670,.5056)	127	0.4893 (-0.4507,.7690)	689	0.8327 (0.6520,.8893)	3292	0.9428 (0.9284,.9529)
22	-0.4367 (-2.7640,.5180)	135	0.5093 (-0.3893,.7752)	733	0.8397 (0.6726,.8924)	3505	0.9452 (0.9328,.9549)
23	-0.3895 (-2.6622,.5301)	144	0.5286 (-0.3295,.7811)	780	0.8463 (0.6921,.8954)	3731	0.9475 (0.9370,.9569)
25	-0.3434 (-2.5617,.5420)	153	0.5471 (-0.2712,.7869)	831	0.8527 (0.7105,.8983)	3972	0.9497 (0.9409,.9587)
27	-0.2984 (-2.4625,.5536)	163	0.5650 (-0.2145,.7926)	884	0.8589 (0.7279,.9012)	4229	0.9519 (0.9445,.9605)
28	-0.2546 (-2.3647,.5649)	174	0.5823 (-0.1593,.7981)	942	0.8648 (0.7444,.9039)	4502	0.9539 (0.9479,.9622)
30	-0.2119 (-2.2683,.5760)	185	0.5989 (-0.1058,.8034)	960	0.8666 (0.7494,.9048)	4553	0.9543 (0.9485,.9625)
32	-0.1703 (-2.1733,.5868)	197	0.6149 (-0.0539,.8087)	1000	0.8702 (0.7593,.9065)	4792	0.9559 (0.9500,.9639)
34	-0.1298 (-2.0797,.5973)	210	0.6303 (-0.0037,.8137)	1002	0.8704 (0.7599,.9066)	5102	0.9577 (0.9513,.9654)
36	-0.0904 (-1.9876,.6077)	223	0.6451 (0.0450,.8187)	1067	0.8758 (0.7745,.9092)	5431	0.9595 (0.9527,.9669)
39	-0.0521 (-1.8970,.6178)	238	0.6594 (0.0919,.8235)	1136	0.8810 (0.7883,.9117)	5782	0.9612 (0.9539,.9683)
41	-0.0148 (-1.8078,.6276)	253	0.6731 (0.1373,.8282)	1209	0.8860 (0.8013,.9141)	6156	0.9629 (0.9552,.9697)
44	0.0213 (-1.7200,.6372)	269	0.6863 (0.1810,.8328)	1288	0.8908 (0.8135,.9165)	6553	0.9645 (0.9564,.9710)
47	0.0564 (-1.6338,.6466)	287	0.6990 (0.2230,.8372)	1297	0.8914 (0.8150,.9168)	6937	0.9658 (0.9575,.9722)
50	0.0905 (-1.5489,.6558)	305	0.7113 (0.2635,.8416)	1371	0.8954 (0.8251,.9188)	6976	0.9660 (0.9576,.9723)
53	0.1236 (-1.4656,.6647)	325	0.7230 (0.3023,.8458)	1459	0.8998 (0.8359,.9210)	7427	0.9674 (0.9587,.9735)
56	0.1556 (-1.3836,.6734)	346	0.7343 (0.3395,.8499)	1553	0.9040 (0.8461,.9232)	7907	0.9688 (0.9598,.9747)
60	0.1867 (-1.3031,.6820)	368	0.7452 (0.3751,.8539)	1654	0.9080 (0.8556,.9254)	8417	0.9701 (0.9609,.9759)
64	0.2168 (-1.2241,.6903)	392	0.7556 (0.4092,.8577)	1761	0.9119 (0.8645,.9282)	8961	0.9714 (0.9619,.9770)
68	0.2459 (-1.1465,.6984)	417	0.7656 (0.4418,.8615)	1874	0.9156 (0.8728,.9309)	9540	0.9726 (0.9629,.9780)
72	0.2742 (-1.0704,.7063)	444	0.7752 (0.4729,.8652)	1995	0.9192 (0.8806,.9335)	10145	0.9738 (0.9638,.9791)
77	0.3015 (-0.9957,.7140)	473	0.7845 (0.5025,.8688)	2124	0.9226 (0.8880,.9360)	10156	0.9738 (0.9638,.9791)
82	0.3279 (-0.9224,.7215)	500	0.7924 (0.5276,.8719)	2261	0.9258 (0.8949,.9387)	10156	0.9738 (0.9638,.9791)
87	0.3534 (-0.8506,.7288)	504	0.7934 (0.5307,.8723)	2408	0.9290 (0.9014,.9413)	10156	0.9738 (0.9638,.9791)
93	0.3781 (-0.7802,.7360)	536	0.8019 (0.5575,.8759)	2563	0.9320 (0.9075,.9438)	10156	0.9738 (0.9638,.9791)
99	0.4019 (-0.7114,.7429)	571	0.8101 (0.5830,.8794)	2729	0.9348 (0.9132,.9463)	223.2	.6451 (.0450,.8187)
105	0.4249 (-0.6439,.7497)	608	0.8179 (0.6073,.8828)	2905	0.9376 (0.9186,.9486)	1459	.8998 (.8359,.9210)
112	0.4472 (-0.5780,.7563)	647	0.8255 (0.6302,.8861)	2957	0.9384 (0.9201,.9492)	3972	.9497 (.9409,.9587)
119	0.4686 (-0.5136,.7628)	653	0.8266 (0.6336,.8866)	3092	0.9402 (0.9236,.9508)		

Table 6.6: Controlled VE with sensitivity analysis as functions of Day 57 Anti Spike IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
20.7	.4248 (-0.4978,.8085)	127	.6918 (0.1244,.8606)	689	.8584 (0.7053,.9063)	3292	.9428 (0.9285,.9530)
22	.4345 (-0.4816,.8103)	135	.6996 (0.1495,.8624)	733	.8628 (0.7199,.9079)	3505	.9452 (0.9328,.9550)
23	.4442 (-0.4649,.8121)	144	.7073 (0.1746,.8641)	780	.8672 (0.7339,.9096)	3731	.9475 (0.9370,.9569)
25	.4540 (-0.4477,.8138)	153	.7149 (0.1997,.8658)	831	.8715 (0.7474,.9113)	3972	.9497 (0.9408,.9587)
27	.4638 (-0.4300,.8156)	163	.7223 (0.2247,.8676)	884	.8757 (0.7603,.9129)	4229	.9518 (0.9444,.9605)
28	.4735 (-0.4120,.8174)	174	.7296 (0.2496,.8693)	942	.8797 (0.7727,.9146)	4502	.9538 (0.9477,.9621)
30	.4833 (-0.3935,.8192)	185	.7368 (0.2744,.8710)	960	.8810 (0.7765,.9151)	4553	.9541 (0.9483,.9624)
32	.4931 (-0.3745,.8210)	197	.7439 (0.2991,.8727)	1000	.8836 (0.7841,.9161)	4792	.9556 (0.9497,.9637)
34	.5029 (-0.3552,.8228)	210	.7508 (0.3235,.8745)	1002	.8837 (0.7845,.9162)	5102	.9574 (0.9510,.9651)
36	.5126 (-0.3355,.8246)	223	.7576 (0.3476,.8762)	1067	.8876 (0.7959,.9178)	5431	.9591 (0.9521,.9665)
39	.5223 (-0.3154,.8264)	238	.7643 (0.3715,.8778)	1136	.8914 (0.8067,.9194)	5782	.9607 (0.9533,.9679)
41	.5319 (-0.2950,.8282)	253	.7708 (0.3950,.8795)	1209	.8951 (0.8171,.9210)	6156	.9622 (0.9543,.9691)
44	.5416 (-0.2742,.8301)	269	.7772 (0.4182,.8812)	1288	.8987 (0.8270,.9225)	6553	.9636 (0.9554,.9703)
47	.5511 (-0.2530,.8319)	287	.7835 (0.4409,.8829)	1297	.8991 (0.8282,.9227)	6937	.9649 (0.9563,.9714)
50	.5606 (-0.2315,.8337)	305	.7896 (0.4633,.8845)	1371	.9022 (0.8364,.9241)	6976	.9650 (0.9564,.9715)
53	.5700 (-0.2096,.8355)	325	.7956 (0.4852,.8862)	1459	.9056 (0.8454,.9256)	7427	.9663 (0.9573,.9726)
56	.5794 (-0.1875,.8373)	346	.8015 (0.5065,.8878)	1553	.9089 (0.8540,.9272)	7907	.9675 (0.9582,.9737)
60	.5886 (-0.1650,.8391)	368	.8073 (0.5274,.8895)	1654	.9122 (0.8621,.9288)	8417	.9687 (0.9590,.9748)
64	.5978 (-0.1422,.8409)	392	.8129 (0.5478,.8911)	1761	.9154 (0.8698,.9310)	8961	.9698 (0.9598,.9757)
68	.6069 (-0.1191,.8428)	417	.8184 (0.5676,.8927)	1874	.9184 (0.8771,.9332)	9540	.9709 (0.9606,.9767)
72	.6159 (-0.0957,.8446)	444	.8238 (0.5868,.8943)	1995	.9214 (0.8840,.9354)	10145	.9719 (0.9613,.9776)
77	.6248 (-0.0720,.8464)	473	.8291 (0.6055,.8960)	2124	.9244 (0.8906,.9375)	10156	.9720 (0.9613,.9776)
82	.6335 (-0.0481,.8482)	500	.8337 (0.6216,.8974)	2261	.9272 (0.8969,.9398)	10156	.9720 (0.9613,.9776)
87	.6422 (-0.0240,.8499)	504	.8343 (0.6236,.8976)	2408	.9300 (0.9029,.9422)	10156	.9720 (0.9613,.9776)
93	.6508 (0.0003,.8517)	536	.8393 (0.6411,.8993)	2563	.9327 (0.9085,.9445)	10156	.9720 (0.9613,.9776)
99	.6592 (0.0249,.8535)	571	.8442 (0.6580,.9011)	2729	.9353 (0.9139,.9467)	223.2	.6451 (.0450,.8187)
105	.6675 (0.0496,.8553)	608	.8490 (0.6744,.9028)	2905	.9379 (0.9190,.9488)	1459	.8998 (.8359,.9210)
112	.6757 (0.0744,.8571)	647	.8538 (0.6901,.9045)	2957	.9386 (0.9204,.9494)	3972	.9497 (.9409,.9587)
119	.6838 (0.0994,.8588)	653	.8545 (0.6925,.9048)	3092	.9404 (0.9239,.9509)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.

Figure 6.9: Marginalized cumulative risk curves ($=s$).



(a) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 1.6$.



(b) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 1.6$.

Figure 6.10: Controlled VE curves ($=s$).




Figure 6.11: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 6.7: Marginalized cumulative risk by Day 164 as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
11.8	.0418 (.0159,.1741)	91	.0204 (.0109,.0627)	655	.0100 (.0072,.0200)	3607	.0054 (.0041,.0071)
13	.0407 (.0157,.1686)	98	.0198 (.0108,.0602)	705	.0097 (.0071,.0192)	3778	.0053 (.0040,.0070)
14	.0397 (.0155,.1632)	106	.0193 (.0106,.0579)	758	.0095 (.0069,.0183)	4064	.0051 (.0039,.0067)
15	.0387 (.0153,.1579)	114	.0188 (.0105,.0555)	763	.0095 (.0069,.0183)	4372	.0050 (.0038,.0064)
16	.0378 (.0151,.1528)	122	.0183 (.0103,.0533)	816	.0092 (.0067,.0176)	4703	.0049 (.0037,.0061)
17	.0368 (.0149,.1477)	131	.0179 (.0102,.0512)	877	.0090 (.0066,.0168)	5059	.0047 (.0036,.0059)
18	.0359 (.0147,.1428)	141	.0174 (.0100,.0491)	944	.0088 (.0064,.0161)	5443	.0046 (.0036,.0057)
20	.0350 (.0145,.1380)	152	.0170 (.0099,.0471)	1000	.0086 (.0063,.0155)	5855	.0045 (.0035,.0055)
21	.0341 (.0143,.1333)	164	.0165 (.0097,.0452)	1015	.0085 (.0063,.0154)	6262	.0044 (.0034,.0053)
23	.0333 (.0141,.1287)	176	.0161 (.0096,.0434)	1092	.0083 (.0061,.0147)	6298	.0044 (.0034,.0053)
25	.0324 (.0139,.1242)	189	.0157 (.0095,.0416)	1139	.0082 (.0060,.0143)	6775	.0043 (.0033,.0051)
26	.0316 (.0137,.1199)	204	.0153 (.0093,.0399)	1175	.0081 (.0060,.0141)	7288	.0042 (.0032,.0049)
28	.0308 (.0136,.1157)	219	.0149 (.0092,.0382)	1264	.0079 (.0058,.0135)	7840	.0040 (.0031,.0048)
31	.0300 (.0134,.1116)	236	.0145 (.0091,.0366)	1360	.0077 (.0057,.0129)	8434	.0039 (.0031,.0047)
33	.0293 (.0132,.1076)	254	.0141 (.0089,.0351)	1463	.0075 (.0055,.0123)	9073	.0038 (.0030,.0046)
35	.0285 (.0130,.1037)	273	.0137 (.0088,.0337)	1573	.0073 (.0054,.0118)	9688	.0037 (.0029,.0046)
38	.0278 (.0128,.0999)	294	.0134 (.0087,.0322)	1693	.0071 (.0053,.0113)	9760	.0037 (.0029,.0046)
41	.0271 (.0127,.0962)	316	.0130 (.0085,.0309)	1817	.0069 (.0051,.0108)	10499	.0036 (.0028,.0045)
44	.0264 (.0125,.0927)	340	.0127 (.0084,.0296)	1821	.0069 (.0051,.0108)	11294	.0035 (.0027,.0045)
47	.0257 (.0123,.0892)	365	.0124 (.0083,.0284)	1959	.0067 (.0050,.0103)	12149	.0034 (.0026,.0044)
51	.0251 (.0122,.0859)	393	.0120 (.0082,.0272)	2107	.0065 (.0049,.0099)	13069	.0034 (.0026,.0043)
55	.0244 (.0120,.0826)	423	.0117 (.0080,.0260)	2267	.0064 (.0048,.0094)	14059	.0033 (.0025,.0043)
59	.0238 (.0118,.0795)	455	.0114 (.0079,.0249)	2438	.0062 (.0047,.0090)	15124	.0032 (.0024,.0042)
63	.0232 (.0117,.0765)	489	.0111 (.0078,.0238)	2623	.0060 (.0046,.0086)	15353	.0032 (.0024,.0042)
68	.0226 (.0115,.0735)	500	.0110 (.0078,.0235)	2821	.0059 (.0044,.0083)	16269	.0031 (.0023,.0042)
73	.0220 (.0114,.0707)	526	.0108 (.0077,.0228)	3035	.0057 (.0043,.0079)	16269	.0031 (.0023,.0042)
79	.0214 (.0112,.0679)	566	.0105 (.0075,.0219)	3265	.0056 (.0042,.0076)	16269	.0031 (.0023,.0042)
85	.0209 (.0111,.0653)	609	.0103 (.0074,.0209)	3512	.0054 (.0041,.0073)	16269	.0031 (.0023,.0042)

Table 6.8: Controlled VE as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
11.8	.5347 (-0.8521,.8226)	98	.7792 (0.3593,.8802)	758	.8943 (0.8049,.9215)	4372	.9442 (0.9322,.9563)
13	.5463 (-0.7933,.8250)	106	.7849 (0.3847,.8818)	763	.8946 (0.8056,.9216)	4703	.9457 (0.9351,.9574)
14	.5576 (-0.7358,.8273)	114	.7904 (0.4092,.8834)	816	.8971 (0.8133,.9233)	5059	.9471 (0.9375,.9584)
15	.5686 (-0.6796,.8296)	122	.7958 (0.4329,.8849)	877	.8998 (0.8213,.9250)	5443	.9485 (0.9399,.9594)
16	.5794 (-0.6246,.8319)	131	.8011 (0.4557,.8865)	944	.9024 (0.8290,.9268)	5855	.9499 (0.9421,.9604)
17	.5900 (-0.5709,.8342)	141	.8062 (0.4777,.8880)	1000	.9044 (0.8349,.9282)	6262	.9511 (0.9437,.9613)
18	.6003 (-0.5185,.8364)	152	.8112 (0.4988,.8895)	1015	.9050 (0.8364,.9286)	6298	.9512 (0.9438,.9613)
20	.6103 (-0.4673,.8386)	164	.8161 (0.5192,.8910)	1092	.9075 (0.8435,.9303)	6775	.9525 (0.9450,.9623)
21	.6201 (-0.4174,.8408)	176	.8209 (0.5389,.8925)	1139	.9089 (0.8474,.9313)	7288	.9537 (0.9460,.9632)
23	.6297 (-0.3687,.8429)	189	.8255 (0.5578,.8939)	1175	.9099 (0.8503,.9320)	7840	.9549 (0.9470,.9641)
25	.6391 (-0.3213,.8450)	204	.8300 (0.5760,.8954)	1264	.9123 (0.8568,.9337)	8434	.9561 (0.9477,.9650)
26	.6482 (-0.2751,.8471)	219	.8345 (0.5935,.8968)	1360	.9146 (0.8630,.9353)	9073	.9573 (0.9484,.9661)
28	.6571 (-0.2301,.8491)	236	.8387 (0.6103,.8982)	1463	.9168 (0.8690,.9368)	9688	.9583 (0.9491,.9670)
31	.6658 (-0.1864,.8512)	254	.8429 (0.6265,.8996)	1573	.9190 (0.8747,.9384)	9760	.9584 (0.9491,.9671)
33	.6743 (-0.1439,.8532)	273	.8470 (0.6421,.9011)	1693	.9211 (0.8801,.9399)	10499	.9595 (0.9498,.9681)
35	.6825 (-0.1026,.8551)	294	.8510 (0.6570,.9025)	1817	.9231 (0.8852,.9413)	11294	.9606 (0.9505,.9690)
38	.6906 (-0.0624,.8571)	316	.8549 (0.6714,.9040)	1821	.9232 (0.8853,.9413)	12149	.9616 (0.9512,.9699)
41	.6985 (-0.0234,.8590)	340	.8587 (0.6852,.9054)	1959	.9252 (0.8903,.9427)	13069	.9626 (0.9518,.9708)
44	.7062 (0.0144,.8609)	365	.8623 (0.6985,.9068)	2107	.9272 (0.8951,.9441)	14059	.9636 (0.9525,.9717)
47	.7137 (0.0510,.8628)	393	.8659 (0.7112,.9081)	2267	.9291 (0.8997,.9455)	15124	.9646 (0.9531,.9728)
51	.7210 (0.0866,.8646)	423	.8694 (0.7234,.9095)	2438	.9309 (0.9041,.9468)	15353	.9648 (0.9532,.9730)
55	.7281 (0.1211,.8664)	455	.8728 (0.7351,.9108)	2623	.9328 (0.9083,.9481)	16269	.9655 (0.9538,.9739)
59	.7351 (0.1544,.8682)	489	.8761 (0.7464,.9121)	2821	.9345 (0.9123,.9494)	16269	.9655 (0.9538,.9739)
63	.7418 (0.1867,.8700)	500	.8771 (0.7496,.9125)	3035	.9362 (0.9161,.9506)	16269	.9655 (0.9538,.9739)
68	.7485 (0.2180,.8718)	526	.8794 (0.7572,.9134)	3265	.9379 (0.9196,.9518)	16269	.9655 (0.9538,.9739)
73	.7549 (0.2482,.8735)	566	.8825 (0.7675,.9148)	3512	.9396 (0.9230,.9530)	26.4	.6482 (-0.2751,.8471)
79	.7612 (0.2774,.8752)	609	.8856 (0.7775,.9163)	3607	.9401 (0.9241,.9534)	877	.8998 (0.8213,.9250)
85	.7673 (0.3056,.8769)	655	.8886 (0.7870,.9178)	3778	.9412 (0.9262,.9541)	5855	.9499 (0.9421,.9604)
91	.7733 (0.3329,.8785)	705	.8915 (0.7961,.9197)	4064	.9427 (0.9293,.9552)		

Table 6.9: Controlled VE with sensitivity analysis as functions of Day 57 Anti RBD IgG (BAU/ml) (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
11.8	.8308 (.3266,.9355)	98	.8721 (.6290,.9306)	758	.9114 (.8364,.9341)	4372	.9444 (.9324,.9564)
13	.8322 (.3369,.9353)	106	.8736 (.6384,.9305)	763	.9115 (.8368,.9342)	4703	.9458 (.9352,.9574)
14	.8336 (.3473,.9351)	114	.8750 (.6476,.9304)	816	.9128 (.8417,.9349)	5059	.9471 (.9376,.9584)
15	.8351 (.3577,.9349)	122	.8764 (.6567,.9303)	877	.9142 (.8469,.9358)	5443	.9485 (.9399,.9594)
16	.8365 (.3683,.9346)	131	.8778 (.6656,.9303)	944	.9155 (.8520,.9367)	5855	.9498 (.9421,.9604)
17	.8379 (.3789,.9344)	141	.8792 (.6744,.9302)	1000	.9166 (.8560,.9374)	6262	.9510 (.9437,.9612)
18	.8393 (.3896,.9342)	152	.8806 (.6831,.9301)	1015	.9169 (.8570,.9376)	6298	.9511 (.9437,.9613)
20	.8407 (.4003,.9340)	164	.8821 (.6916,.9301)	1092	.9183 (.8618,.9385)	6775	.9523 (.9448,.9622)
21	.8422 (.4111,.9338)	176	.8835 (.7000,.9301)	1139	.9191 (.8645,.9390)	7288	.9535 (.9458,.9630)
23	.8436 (.4218,.9336)	189	.8849 (.7082,.9300)	1175	.9197 (.8665,.9394)	7840	.9546 (.9466,.9638)
25	.8450 (.4326,.9334)	204	.8863 (.7163,.9300)	1264	.9210 (.8711,.9403)	8434	.9556 (.9471,.9646)
26	.8464 (.4435,.9333)	219	.8877 (.7242,.9300)	1360	.9224 (.8756,.9412)	9073	.9566 (.9476,.9656)
28	.8479 (.4543,.9331)	236	.8891 (.7320,.9300)	1463	.9238 (.8800,.9422)	9688	.9575 (.9480,.9663)
31	.8493 (.4650,.9329)	254	.8905 (.7396,.9300)	1573	.9252 (.8842,.9431)	9760	.9576 (.9481,.9664)
33	.8507 (.4758,.9327)	273	.8919 (.7471,.9301)	1693	.9265 (.8884,.9440)	10499	.9585 (.9485,.9673)
35	.8522 (.4866,.9325)	294	.8933 (.7544,.9302)	1817	.9279 (.8923,.9449)	11294	.9594 (.9490,.9681)
38	.8536 (.4972,.9324)	316	.8947 (.7616,.9303)	1821	.9279 (.8924,.9449)	12149	.9602 (.9494,.9688)
41	.8550 (.5079,.9322)	340	.8961 (.7686,.9304)	1959	.9293 (.8963,.9459)	13069	.9610 (.9497,.9695)
44	.8564 (.5185,.9320)	365	.8975 (.7755,.9306)	2107	.9307 (.9002,.9468)	14059	.9618 (.9501,.9703)
47	.8579 (.5290,.9319)	393	.8989 (.7822,.9307)	2267	.9320 (.9039,.9478)	15124	.9625 (.9504,.9712)
51	.8593 (.5394,.9317)	423	.9003 (.7888,.9309)	2438	.9334 (.9075,.9487)	15353	.9627 (.9505,.9714)
55	.8607 (.5498,.9316)	455	.9017 (.7952,.9310)	2623	.9348 (.9111,.9497)	16269	.9633 (.9507,.9722)
59	.8622 (.5601,.9314)	489	.9031 (.8015,.9312)	2821	.9361 (.9145,.9506)	16269	.9633 (.9507,.9722)
63	.8636 (.5703,.9313)	500	.9035 (.8034,.9313)	3035	.9375 (.9178,.9516)	16269	.9633 (.9507,.9722)
68	.8650 (.5803,.9312)	526	.9045 (.8077,.9314)	3265	.9389 (.9208,.9525)	16269	.9633 (.9507,.9722)
73	.8664 (.5903,.9311)	566	.9058 (.8137,.9317)	3512	.9403 (.9239,.9535)	26.4	.6482 (-0.2751,.8471)
79	.8679 (.6002,.9309)	609	.9072 (.8196,.9321)	3607	.9408 (.9249,.9539)	877	.8998 (0.8213,.9250)
85	.8693 (.6099,.9308)	655	.9086 (.8253,.9326)	3778	.9416 (.9268,.9545)	5855	.9499 (0.9421,.9604)
91	.8707 (.6195,.9307)	705	.9100 (.8309,.9334)	4064	.9430 (.9296,.9554)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 2.4.

Figure 6.12: Marginalized cumulative risk curves ($=s$).



(a) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 2.4$.



(b) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 2.4$.

Figure 6.13: Controlled VE curves ($=s$).




Figure 6.14: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 6.10: Marginalized cumulative risk by Day 164 as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
13.7	.0264 (.0149,.0498)	90	.0107 (.0081,.0159)	454	.0049 (.0039,.0059)	2019	.0024 (.0019,.0035)
15	.0256 (.0146,.0479)	97	.0104 (.0079,.0152)	457	.0049 (.0039,.0059)	2027	.0024 (.0019,.0035)
16	.0248 (.0143,.0460)	104	.0100 (.0077,.0146)	489	.0047 (.0037,.0057)	2160	.0023 (.0018,.0034)
17	.0240 (.0141,.0442)	111	.0097 (.0075,.0140)	500	.0047 (.0037,.0056)	2311	.0022 (.0017,.0033)
18	.0232 (.0138,.0425)	113	.0096 (.0074,.0138)	523	.0046 (.0036,.0055)	2440	.0022 (.0017,.0033)
19	.0225 (.0135,.0408)	118	.0094 (.0072,.0134)	560	.0044 (.0035,.0053)	2472	.0021 (.0017,.0033)
20	.0218 (.0133,.0392)	127	.0091 (.0070,.0129)	599	.0043 (.0034,.0051)	2645	.0021 (.0016,.0032)
22	.0211 (.0130,.0377)	136	.0088 (.0068,.0123)	641	.0041 (.0033,.0049)	2830	.0020 (.0015,.0031)
23	.0204 (.0128,.0362)	145	.0085 (.0066,.0118)	673	.0040 (.0032,.0048)	3028	.0019 (.0015,.0031)
25	.0198 (.0125,.0347)	150	.0084 (.0065,.0116)	686	.0040 (.0032,.0048)	3239	.0019 (.0014,.0030)
27	.0192 (.0123,.0334)	155	.0083 (.0064,.0114)	733	.0039 (.0031,.0047)	3465	.0018 (.0014,.0030)
29	.0186 (.0120,.0320)	166	.0080 (.0062,.0109)	785	.0038 (.0030,.0046)	3707	.0018 (.0013,.0029)
31	.0180 (.0118,.0308)	178	.0077 (.0060,.0104)	839	.0036 (.0029,.0045)	3966	.0017 (.0012,.0028)
33	.0174 (.0116,.0295)	190	.0075 (.0058,.0100)	898	.0035 (.0028,.0044)	4243	.0016 (.0012,.0028)
35	.0169 (.0113,.0283)	191	.0075 (.0058,.0100)	909	.0035 (.0028,.0044)	4540	.0016 (.0011,.0027)
38	.0163 (.0111,.0272)	203	.0072 (.0056,.0096)	961	.0034 (.0027,.0043)	4857	.0015 (.0011,.0027)
40	.0158 (.0109,.0261)	218	.0070 (.0055,.0092)	1000	.0033 (.0027,.0043)	5196	.0015 (.0011,.0026)
43	.0153 (.0107,.0251)	233	.0068 (.0053,.0088)	1028	.0033 (.0026,.0042)	5559	.0014 (.0010,.0026)
46	.0148 (.0105,.0240)	249	.0066 (.0051,.0085)	1100	.0032 (.0026,.0041)	5947	.0014 (.0010,.0025)
49	.0143 (.0103,.0231)	266	.0064 (.0050,.0081)	1177	.0031 (.0025,.0041)	6362	.0014 (.0009,.0025)
53	.0139 (.0100,.0221)	285	.0061 (.0048,.0078)	1259	.0030 (.0024,.0040)	6807	.0013 (.0009,.0024)
56	.0134 (.0098,.0212)	305	.0059 (.0047,.0075)	1347	.0029 (.0023,.0039)	7282	.0013 (.0009,.0024)
60	.0130 (.0096,.0204)	326	.0058 (.0045,.0072)	1441	.0028 (.0023,.0038)	7791	.0012 (.0008,.0023)
65	.0126 (.0094,.0196)	330	.0057 (.0045,.0072)	1491	.0027 (.0022,.0038)	8335	.0012 (.0008,.0023)
69	.0122 (.0091,.0188)	349	.0056 (.0044,.0069)	1541	.0027 (.0022,.0038)	8917	.0011 (.0008,.0022)
74	.0118 (.0089,.0180)	373	.0054 (.0042,.0067)	1649	.0026 (.0021,.0037)	9540	.0011 (.0007,.0022)
79	.0114 (.0086,.0173)	399	.0052 (.0041,.0064)	1764	.0025 (.0020,.0036)	10206	.0011 (.0007,.0022)
85	.0111 (.0084,.0166)	427	.0050 (.0040,.0061)	1887	.0024 (.0020,.0035)	10919	.0010 (.0007,.0021)

Table 6.11: Controlled VE as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).


s	Estimate	s	Estimate	s	Estimate	s	Estimate
13.7	.7061 (.4693,.8350)	97	.8845 (.8378,.9101)	489	.9473 (.9396,.9573)	2311	.9753 (.9631,.9802)
15	.7153 (.4899,.8382)	104	.8882 (.8444,.9127)	500	.9479 (.9404,.9578)	2440	.9759 (.9637,.9809)
16	.7242 (.5098,.8413)	111	.8918 (.8508,.9152)	523	.9490 (.9419,.9587)	2472	.9761 (.9638,.9810)
17	.7329 (.5289,.8444)	113	.8931 (.8530,.9161)	560	.9507 (.9436,.9600)	2645	.9769 (.9645,.9818)
18	.7412 (.5473,.8474)	118	.8953 (.8569,.9176)	599	.9523 (.9449,.9612)	2830	.9776 (.9652,.9825)
19	.7494 (.5651,.8504)	127	.8987 (.8628,.9200)	641	.9538 (.9461,.9624)	3028	.9783 (.9659,.9832)
20	.7573 (.5822,.8533)	136	.9019 (.8685,.9223)	673	.9549 (.9469,.9633)	3239	.9790 (.9666,.9839)
22	.7649 (.5987,.8561)	145	.9051 (.8739,.9247)	686	.9553 (.9473,.9636)	3465	.9797 (.9672,.9845)
23	.7723 (.6145,.8589)	150	.9067 (.8767,.9260)	733	.9568 (.9484,.9647)	3707	.9804 (.9679,.9852)
25	.7795 (.6298,.8617)	155	.9081 (.8791,.9271)	785	.9582 (.9494,.9658)	3966	.9810 (.9685,.9857)
27	.7865 (.6445,.8644)	166	.9111 (.8841,.9293)	839	.9595 (.9504,.9669)	4243	.9816 (.9691,.9863)
29	.7932 (.6587,.8670)	178	.9139 (.8888,.9315)	898	.9608 (.9513,.9679)	4540	.9822 (.9697,.9869)
31	.7998 (.6723,.8696)	190	.9167 (.8934,.9336)	909	.9611 (.9515,.9681)	4857	.9828 (.9703,.9874)
33	.8061 (.6854,.8721)	191	.9169 (.8938,.9338)	961	.9621 (.9523,.9689)	5196	.9834 (.9709,.9880)
35	.8123 (.6980,.8746)	203	.9194 (.8978,.9357)	1000	.9628 (.9528,.9695)	5559	.9839 (.9715,.9885)
38	.8182 (.7101,.8770)	218	.9220 (.9021,.9377)	1028	.9633 (.9532,.9699)	5947	.9844 (.9720,.9890)
40	.8240 (.7218,.8794)	233	.9245 (.9061,.9396)	1100	.9645 (.9541,.9708)	6362	.9849 (.9726,.9894)
43	.8296 (.7330,.8818)	249	.9269 (.9100,.9415)	1177	.9657 (.9550,.9717)	6807	.9854 (.9731,.9899)
46	.8350 (.7438,.8841)	266	.9293 (.9136,.9433)	1259	.9668 (.9559,.9726)	7282	.9859 (.9736,.9903)
49	.8403 (.7541,.8863)	285	.9315 (.9170,.9451)	1347	.9678 (.9568,.9735)	7791	.9864 (.9742,.9907)
53	.8454 (.7641,.8885)	305	.9337 (.9202,.9468)	1441	.9689 (.9576,.9743)	8335	.9868 (.9747,.9911)
56	.8503 (.7737,.8907)	326	.9359 (.9233,.9484)	1491	.9694 (.9580,.9747)	8917	.9872 (.9752,.9915)
60	.8551 (.7828,.8928)	330	.9363 (.9239,.9487)	1541	.9699 (.9585,.9752)	9540	.9876 (.9757,.9919)
65	.8597 (.7917,.8949)	349	.9380 (.9263,.9500)	1649	.9709 (.9593,.9760)	10206	.9880 (.9761,.9922)
69	.8642 (.8002,.8970)	373	.9400 (.9292,.9516)	1764	.9718 (.9601,.9768)	10919	.9884 (.9766,.9925)
74	.8685 (.8083,.8992)	399	.9419 (.9320,.9531)	1887	.9727 (.9608,.9777)	(,)	
79	.8727 (.8161,.9021)	427	.9438 (.9346,.9546)	2019	.9736 (.9616,.9786)	127	.8987 (.8628,.9200)
85	.8768 (.8236,.9048)	454	.9454 (.9369,.9558)	2027	.9737 (.9617,.9786)	560	.9507 (.9436,.9600)
90	.8807 (.8309,.9075)	457	.9456 (.9372,.9560)	2160	.9745 (.9624,.9794)		

Table 6.12: Controlled VE with sensitivity analysis as functions of Day 57 Pseudovirus-nAb cID50 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
13.7	.8179 (.6713,.8978)	97	.8991 (.8582,.9214)	489	.9473 (.9396,.9573)	2311	.9722 (.9584,.9777)
15	.8212 (.6797,.8984)	104	.9014 (.8627,.9230)	500	.9479 (.9404,.9578)	2440	.9727 (.9588,.9783)
16	.8244 (.6879,.8990)	111	.9037 (.8671,.9245)	523	.9490 (.9419,.9587)	2472	.9728 (.9589,.9784)
17	.8276 (.6960,.8996)	113	.9045 (.8687,.9250)	560	.9506 (.9436,.9599)	2645	.9735 (.9593,.9791)
18	.8308 (.7040,.9002)	118	.9059 (.8715,.9260)	599	.9522 (.9447,.9611)	2830	.9741 (.9597,.9798)
19	.8339 (.7118,.9009)	127	.9082 (.8757,.9275)	641	.9536 (.9459,.9623)	3028	.9747 (.9601,.9804)
20	.8370 (.7195,.9015)	136	.9104 (.8798,.9290)	673	.9547 (.9466,.9630)	3239	.9752 (.9605,.9810)
22	.8401 (.7270,.9021)	145	.9125 (.8838,.9307)	686	.9550 (.9469,.9633)	3465	.9758 (.9609,.9815)
23	.8431 (.7344,.9028)	150	.9137 (.8859,.9315)	733	.9564 (.9479,.9644)	3707	.9763 (.9612,.9821)
25	.8461 (.7416,.9034)	155	.9147 (.8877,.9323)	785	.9576 (.9487,.9654)	3966	.9769 (.9616,.9826)
27	.8491 (.7487,.9041)	166	.9168 (.8916,.9339)	839	.9588 (.9495,.9663)	4243	.9774 (.9619,.9831)
29	.8520 (.7557,.9048)	178	.9189 (.8953,.9355)	898	.9600 (.9503,.9672)	4540	.9779 (.9623,.9836)
31	.8549 (.7625,.9055)	190	.9210 (.8989,.9371)	909	.9602 (.9504,.9674)	4857	.9783 (.9626,.9841)
33	.8577 (.7691,.9062)	191	.9211 (.8992,.9372)	961	.9611 (.9510,.9681)	5196	.9788 (.9629,.9846)
35	.8606 (.7757,.9069)	203	.9230 (.9025,.9386)	1000	.9617 (.9515,.9686)	5559	.9792 (.9632,.9851)
38	.8633 (.7821,.9076)	218	.9251 (.9059,.9402)	1028	.9622 (.9517,.9689)	5947	.9797 (.9635,.9856)
40	.8661 (.7883,.9083)	233	.9270 (.9093,.9417)	1100	.9632 (.9524,.9697)	6362	.9801 (.9638,.9860)
43	.8688 (.7945,.9090)	249	.9290 (.9126,.9432)	1177	.9642 (.9531,.9705)	6807	.9805 (.9641,.9865)
46	.8715 (.8005,.9097)	266	.9310 (.9156,.9447)	1259	.9651 (.9537,.9712)	7282	.9809 (.9644,.9869)
49	.8742 (.8063,.9105)	285	.9329 (.9186,.9461)	1347	.9660 (.9543,.9719)	7791	.9813 (.9646,.9873)
53	.8768 (.8121,.9112)	305	.9348 (.9214,.9476)	1441	.9669 (.9549,.9726)	8335	.9817 (.9649,.9877)
56	.8794 (.8177,.9120)	326	.9366 (.9242,.9490)	1491	.9673 (.9552,.9730)	8917	.9821 (.9652,.9881)
60	.8820 (.8232,.9127)	330	.9370 (.9247,.9493)	1541	.9677 (.9555,.9734)	9540	.9824 (.9654,.9884)
65	.8845 (.8285,.9135)	349	.9385 (.9269,.9505)	1649	.9685 (.9560,.9741)	10206	.9828 (.9657,.9888)
69	.8870 (.8337,.9143)	373	.9403 (.9296,.9519)	1764	.9693 (.9565,.9748)	10919	.9831 (.9659,.9891)
74	.8895 (.8389,.9153)	399	.9421 (.9322,.9533)	1887	.9701 (.9570,.9755)	(,)	
79	.8919 (.8439,.9168)	427	.9439 (.9347,.9546)	2019	.9708 (.9575,.9763)	127	.8987 (.8628,.9200)
85	.8943 (.8487,.9184)	454	.9454 (.9369,.9558)	2027	.9708 (.9575,.9763)	560	.9507 (.9436,.9600)
90	.8967 (.8535,.9199)	457	.9456 (.9372,.9560)	2160	.9715 (.9580,.9770)		




(a) Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




(b) Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 15$.

Figure 6.15: Marginalized cumulative risk curves ($=s$).



(a) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 15$.



(b) Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 15$.

Figure 6.16: Controlled VE curves ($=s$).




Figure 6.17: Marginalized cumulative risk curves and controlled VE curves ($\geq s$).

Table 6.13: Marginalized cumulative risk by Day 164 as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
25.3	.0197 (.0070,.0362)	155	.0086 (.0050,.0115)	644	.0045 (.0036,.0052)	2677	.0023 (.0015,.0035)
27	.0192 (.0069,.0348)	165	.0084 (.0050,.0111)	687	.0043 (.0035,.0050)	2856	.0022 (.0015,.0035)
29	.0186 (.0068,.0333)	166	.0083 (.0050,.0110)	733	.0042 (.0034,.0049)	3047	.0022 (.0014,.0034)
31	.0181 (.0067,.0320)	177	.0081 (.0049,.0106)	749	.0042 (.0034,.0048)	3250	.0021 (.0014,.0034)
33	.0175 (.0067,.0307)	188	.0079 (.0049,.0102)	782	.0041 (.0033,.0048)	3468	.0020 (.0013,.0033)
35	.0170 (.0066,.0294)	201	.0076 (.0048,.0099)	835	.0040 (.0032,.0047)	3699	.0020 (.0012,.0033)
37	.0165 (.0065,.0282)	214	.0074 (.0048,.0095)	891	.0038 (.0031,.0046)	3947	.0019 (.0012,.0033)
40	.0160 (.0064,.0271)	216	.0074 (.0048,.0094)	950	.0037 (.0030,.0045)	4211	.0019 (.0011,.0032)
42	.0156 (.0064,.0260)	229	.0072 (.0047,.0091)	958	.0037 (.0030,.0045)	4492	.0018 (.0011,.0032)
45	.0151 (.0063,.0249)	244	.0070 (.0047,.0088)	1000	.0036 (.0029,.0044)	4793	.0018 (.0010,.0031)
48	.0147 (.0062,.0239)	260	.0068 (.0046,.0085)	1014	.0036 (.0029,.0044)	5113	.0017 (.0010,.0031)
52	.0143 (.0061,.0229)	278	.0066 (.0045,.0082)	1081	.0035 (.0028,.0043)	5455	.0017 (.0010,.0031)
55	.0138 (.0061,.0219)	285	.0065 (.0045,.0080)	1154	.0034 (.0027,.0042)	5820	.0016 (.0009,.0030)
59	.0134 (.0060,.0210)	296	.0064 (.0045,.0079)	1231	.0033 (.0026,.0041)	6209	.0016 (.0009,.0030)
63	.0130 (.0059,.0201)	316	.0062 (.0044,.0076)	1313	.0032 (.0025,.0041)	6625	.0015 (.0008,.0029)
67	.0127 (.0059,.0193)	337	.0060 (.0044,.0073)	1401	.0031 (.0023,.0040)	7068	.0015 (.0008,.0029)
71	.0123 (.0058,.0185)	360	.0058 (.0043,.0070)	1452	.0031 (.0023,.0040)	7540	.0014 (.0008,.0029)
76	.0119 (.0057,.0177)	384	.0057 (.0042,.0068)	1495	.0030 (.0023,.0040)	8044	.0014 (.0007,.0028)
81	.0116 (.0057,.0170)	410	.0055 (.0041,.0065)	1595	.0029 (.0022,.0039)	8582	.0013 (.0007,.0028)
87	.0112 (.0056,.0163)	437	.0053 (.0041,.0063)	1701	.0028 (.0021,.0039)	9156	.0013 (.0007,.0028)
92	.0109 (.0055,.0156)	440	.0053 (.0041,.0063)	1815	.0028 (.0020,.0038)	9769	.0013 (.0006,.0027)
99	.0106 (.0055,.0150)	466	.0052 (.0040,.0061)	1840	.0027 (.0020,.0038)	10422	.0012 (.0006,.0027)
105	.0103 (.0054,.0145)	497	.0050 (.0039,.0059)	1936	.0027 (.0019,.0038)	11119	.0012 (.0006,.0027)
112	.0100 (.0053,.0139)	500	.0050 (.0039,.0059)	2066	.0026 (.0018,.0037)	11862	.0012 (.0006,.0026)
120	.0097 (.0053,.0134)	531	.0049 (.0039,.0057)	2204	.0025 (.0017,.0037)	12656	.0011 (.0005,.0026)
128	.0094 (.0052,.0129)	566	.0047 (.0038,.0055)	2349	.0024 (.0017,.0036)	13502	.0011 (.0005,.0026)
136	.0091 (.0052,.0124)	581	.0047 (.0038,.0055)	2352	.0024 (.0017,.0036)	14405	.0011 (.0005,.0025)
145	.0089 (.0051,.0120)	604	.0046 (.0037,.0053)	2509	.0024 (.0016,.0036)	15368	.0010 (.0005,.0025)

Table 6.14: Controlled VE as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
25.3	.7804 (.5922,.9207)	165	.9070 (.8811,.9433)	733	.9532 (.9463,.9607)	3250	.9766 (.9619,.9846)
27	.7867 (.6089,.9217)	166	.9071 (.8814,.9433)	749	.9537 (.9467,.9610)	3468	.9773 (.9624,.9853)
29	.7929 (.6249,.9226)	177	.9097 (.8862,.9440)	782	.9546 (.9474,.9619)	3699	.9779 (.9629,.9859)
31	.7989 (.6402,.9234)	188	.9124 (.8907,.9446)	835	.9560 (.9485,.9632)	3947	.9786 (.9634,.9865)
33	.8047 (.6549,.9243)	201	.9149 (.8949,.9452)	891	.9573 (.9496,.9645)	4211	.9792 (.9638,.9871)
35	.8104 (.6690,.9252)	214	.9174 (.8988,.9459)	950	.9585 (.9507,.9658)	4492	.9798 (.9643,.9877)
37	.8159 (.6826,.9260)	216	.9178 (.8994,.9460)	958	.9587 (.9508,.9659)	4793	.9804 (.9647,.9882)
40	.8213 (.6957,.9269)	229	.9199 (.9027,.9465)	1000	.9595 (.9514,.9667)	5113	.9810 (.9652,.9887)
42	.8265 (.7082,.9277)	244	.9222 (.9064,.9471)	1014	.9598 (.9516,.9670)	5455	.9816 (.9656,.9892)
45	.8315 (.7203,.9286)	260	.9245 (.9099,.9477)	1081	.9610 (.9525,.9681)	5820	.9821 (.9661,.9897)
48	.8364 (.7319,.9294)	278	.9267 (.9133,.9483)	1154	.9621 (.9531,.9694)	6209	.9827 (.9665,.9901)
52	.8412 (.7430,.9302)	285	.9276 (.9146,.9486)	1231	.9632 (.9537,.9707)	6625	.9832 (.9670,.9905)
55	.8458 (.7537,.9310)	296	.9289 (.9166,.9489)	1313	.9643 (.9543,.9719)	7068	.9837 (.9674,.9909)
59	.8503 (.7639,.9318)	316	.9310 (.9198,.9495)	1401	.9654 (.9549,.9731)	7540	.9842 (.9678,.9913)
63	.8547 (.7737,.9326)	337	.9330 (.9227,.9504)	1452	.9659 (.9552,.9737)	8044	.9846 (.9681,.9917)
67	.8589 (.7832,.9333)	360	.9350 (.9254,.9512)	1495	.9664 (.9555,.9742)	8582	.9851 (.9685,.9921)
71	.8631 (.7922,.9341)	384	.9369 (.9280,.9520)	1595	.9674 (.9560,.9753)	9156	.9855 (.9689,.9924)
76	.8671 (.8009,.9349)	410	.9388 (.9305,.9528)	1701	.9684 (.9566,.9763)	9769	.9860 (.9692,.9927)
81	.8709 (.8092,.9356)	437	.9406 (.9329,.9536)	1815	.9693 (.9572,.9773)	10422	.9864 (.9696,.9931)
87	.8747 (.8172,.9364)	440	.9408 (.9332,.9537)	1840	.9695 (.9573,.9775)	11119	.9868 (.9699,.9934)
92	.8784 (.8249,.9371)	466	.9423 (.9352,.9544)	1936	.9702 (.9577,.9783)	11862	.9872 (.9703,.9936)
99	.8820 (.8323,.9378)	497	.9440 (.9374,.9551)	2066	.9711 (.9583,.9792)	12656	.9875 (.9706,.9939)
105	.8854 (.8393,.9385)	500	.9442 (.9375,.9552)	2204	.9719 (.9588,.9800)	13502	.9879 (.9710,.9942)
112	.8888 (.8461,.9392)	531	.9457 (.9394,.9559)	2349	.9728 (.9593,.9808)	14405	.9883 (.9713,.9944)
120	.8920 (.8525,.9399)	566	.9473 (.9412,.9566)	2352	.9728 (.9593,.9809)	15368	.9886 (.9716,.9947)
128	.8952 (.8588,.9406)	581	.9479 (.9418,.9569)	2509	.9736 (.9599,.9817)	(,)	
136	.8983 (.8647,.9413)	604	.9488 (.9427,.9573)	2677	.9744 (.9604,.9824)	145	.9013 (.8704,.9420)
145	.9013 (.8704,.9420)	644	.9504 (.9439,.9585)	2856	.9751 (.9609,.9832)	644	.9504 (.9439,.9585)
155	.9042 (.8759,.9427)	687	.9518 (.9451,.9596)	3047	.9759 (.9614,.9839)		

Table 6.15: Controlled VE with sensitivity analysis as functions of Day 57 Pseudovirus-nAb cID80 (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

s	Estimate	s	Estimate	s	Estimate	s	Estimate
25.3	.8696 (.7579,.9530)	165	.9174 (.8944,.9496)	733	.9530 (.9460,.9605)	3250	.9713 (.9534,.9812)
27	.8713 (.7640,.9527)	166	.9174 (.8946,.9496)	749	.9534 (.9463,.9608)	3468	.9718 (.9534,.9817)
29	.8730 (.7700,.9525)	177	.9190 (.8978,.9497)	782	.9542 (.9470,.9616)	3699	.9723 (.9534,.9823)
31	.8747 (.7758,.9523)	188	.9206 (.9009,.9498)	835	.9554 (.9479,.9628)	3947	.9728 (.9534,.9829)
33	.8764 (.7816,.9521)	201	.9221 (.9038,.9499)	891	.9565 (.9488,.9639)	4211	.9732 (.9534,.9834)
35	.8781 (.7872,.9519)	214	.9237 (.9065,.9500)	950	.9576 (.9496,.9650)	4492	.9737 (.9533,.9839)
37	.8798 (.7927,.9517)	216	.9240 (.9069,.9500)	958	.9577 (.9497,.9651)	4793	.9741 (.9533,.9844)
40	.8814 (.7981,.9515)	229	.9253 (.9093,.9501)	1000	.9584 (.9502,.9658)	5113	.9745 (.9533,.9848)
42	.8831 (.8035,.9513)	244	.9269 (.9120,.9503)	1014	.9586 (.9503,.9660)	5455	.9749 (.9532,.9853)
45	.8848 (.8087,.9511)	260	.9285 (.9146,.9505)	1081	.9596 (.9508,.9670)	5820	.9753 (.9531,.9857)
48	.8864 (.8139,.9510)	278	.9301 (.9173,.9507)	1154	.9605 (.9511,.9682)	6209	.9757 (.9531,.9861)
52	.8881 (.8189,.9508)	285	.9307 (.9183,.9507)	1231	.9614 (.9514,.9693)	6625	.9760 (.9530,.9865)
55	.8898 (.8239,.9507)	296	.9316 (.9198,.9509)	1313	.9623 (.9517,.9703)	7068	.9764 (.9529,.9869)
59	.8914 (.8287,.9505)	316	.9332 (.9224,.9512)	1401	.9631 (.9519,.9713)	7540	.9768 (.9528,.9873)
63	.8931 (.8335,.9504)	337	.9348 (.9248,.9517)	1452	.9635 (.9520,.9719)	8044	.9771 (.9526,.9877)
67	.8947 (.8382,.9503)	360	.9363 (.9270,.9522)	1495	.9639 (.9521,.9723)	8582	.9774 (.9524,.9880)
71	.8963 (.8427,.9501)	384	.9379 (.9291,.9528)	1595	.9646 (.9523,.9732)	9156	.9778 (.9522,.9884)
76	.8980 (.8472,.9500)	410	.9395 (.9313,.9534)	1701	.9654 (.9525,.9741)	9769	.9781 (.9520,.9887)
81	.8996 (.8516,.9499)	437	.9410 (.9334,.9540)	1815	.9661 (.9527,.9749)	10422	.9784 (.9518,.9890)
87	.9012 (.8559,.9498)	440	.9412 (.9336,.9541)	1840	.9662 (.9527,.9751)	11119	.9787 (.9516,.9893)
92	.9029 (.8602,.9498)	466	.9426 (.9355,.9546)	1936	.9667 (.9528,.9757)	11862	.9790 (.9514,.9896)
99	.9045 (.8643,.9497)	497	.9442 (.9375,.9552)	2066	.9674 (.9529,.9765)	12656	.9793 (.9511,.9899)
105	.9061 (.8683,.9496)	500	.9443 (.9377,.9553)	2204	.9680 (.9530,.9772)	13502	.9796 (.9509,.9902)
112	.9077 (.8723,.9496)	531	.9457 (.9395,.9559)	2349	.9686 (.9531,.9779)	14405	.9799 (.9507,.9904)
120	.9093 (.8762,.9496)	566	.9473 (.9412,.9566)	2352	.9686 (.9531,.9779)	15368	.9801 (.9504,.9907)
128	.9110 (.8800,.9496)	581	.9479 (.9418,.9569)	2509	.9692 (.9532,.9786)	(,)	
136	.9126 (.8837,.9496)	604	.9488 (.9427,.9573)	2677	.9698 (.9533,.9793)	145	.9013 (.8704,.9420)
145	.9142 (.8874,.9496)	644	.9503 (.9438,.9584)	2856	.9703 (.9533,.9799)	644	.9504 (.9439,.9585)
155	.9158 (.8909,.9496)	687	.9517 (.9450,.9595)	3047	.9708 (.9534,.9806)		

Chapter 7

Univariate CoR: Nonparametric Threshold Modeling ($>= s$)

An extension of the unadjusted nonparametric threshold-searching approach developed in Donovan, Hudgens, and Gilbert (2019), the covariate-adjusted TMLE-based approach developed by van der Laan, Zhang, Gilbert (submitted) is used to estimate the so-called threshold-response function $E_X[E[Y | S \geq s, X, A = 1] | A = 1]$ for a range of thresholds s . Here, X is a set of baseline characteristics, $A = 1$ represents the vaccine group, S is the biomarker/immune-response/correlate of interest, and Y is the indicator of COVID disease before some time point t_f . This parameter can be viewed as a causal/covariate-adjusted version of the parameter $P(Y = 1 | S \geq s, A = 1)$. Intuitively, the threshold-response at a given threshold is the expected probability of obtaining COVID disease if one experiences a marker/immune-response value above that threshold. The threshold-response function is estimated for each of the four Day 57 antibody markers, in each case adjusting for the baseline covariates: baseline risk score, high risk indicator, and underrepresented minority status. A restrictive but flexible specification of the Highly Adaptive Lasso estimator is used for the covariate adjustment. A number of plots and tables are reported:

1. A plot and table with risk estimates and point-wise 95% confidence intervals
2. A plot and table with risk estimates and simultaneous 95% confidence bands
3. Monotone-corrected versions of 1 and 2.

A reverse cumulative distribution function curve estimated by the IPW NPMLE of the marker values is superimposed on the threshold-response plots and a dashed red line is added to mark the threshold value after which no more events are observed.

The blue dots on the plots represent the risk predictions at marker values where there was an observed COVID-19 case.

7.1 Plots and Tables with estimates and pointwise confidence intervals for Day 57

MOCK

7.1.1 Day 57 bindSpike




Figure 7.1: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 7.1: Table of risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.316	$2.07 * 10^1$	0.00491	0.00309	0.00673
2.699	$5.00 * 10^2$	0.00453	0.00266	0.00640
2.815	$6.53 * 10^2$	0.00450	0.00253	0.00647
2.982	$9.59 * 10^2$	0.00357	0.00190	0.00524
3.000	$1.00 * 10^3$	0.00357	0.00190	0.00524
3.113	$1.30 * 10^3$	0.00347	0.00175	0.00519
3.471	$2.96 * 10^3$	0.00266	0.00064	0.00467
3.658	$4.55 * 10^3$	0.00185	0.00000	0.00444
3.841	$6.93 * 10^3$	0.00148	0.00000	0.00474
4.006	$1.01 * 10^4$	0.00142	0.00000	0.01796
4.007	$1.02 * 10^4$	0.00142	0.00000	0.01796
4.007	$1.02 * 10^4$	0.00142	0.00000	0.01796
4.007	$1.02 * 10^4$	0.00142	0.00000	0.01796

7.1.2 Day 57 bindRBD




Figure 7.2: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 7.2: Table of risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.073	$1.18 * 10^1$	0.00487	0.00305	0.00668
2.699	$5.00 * 10^2$	0.00469	0.00274	0.00664
2.882	$7.62 * 10^2$	0.00462	0.00261	0.00663
3.000	$1.00 * 10^3$	0.00462	0.00261	0.00663
3.056	$1.14 * 10^3$	0.00408	0.00220	0.00597
3.259	$1.82 * 10^3$	0.00387	0.00193	0.00581
3.557	$3.61 * 10^3$	0.00322	0.00090	0.00553
3.797	$6.27 * 10^3$	0.00356	0.00000	0.00768
3.986	$9.68 * 10^3$	0.00420	0.00000	0.01299
4.186	$1.53 * 10^4$	0.00377	0.00000	0.02060
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950

7.1.3 Day 57 pseudoneutid50




Figure 7.3: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 7.3: Table of risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals.

log ₁₀ -Threshold	Threshold	Risk estimate	CI left	CI right
1.135	1.36 * 10 ¹	0.00484	0.00302	0.00666
2.055	1.14 * 10 ²	0.00437	0.00244	0.00631
2.177	1.50 * 10 ²	0.00444	0.00236	0.00653
2.281	1.91 * 10 ²	0.00459	0.00233	0.00686
2.519	3.30 * 10 ²	0.00404	0.00153	0.00655
2.657	4.54 * 10 ²	0.00280	0.00053	0.00507
2.699	5.00 * 10 ²	0.00297	0.00050	0.00545
2.828	6.73 * 10 ²	0.00336	0.00017	0.00655
2.959	9.10 * 10 ²	0.00351	0.00000	0.00736
3.000	1.00 * 10 ³	0.00270	0.00000	0.00637
3.174	1.49 * 10 ³	0.00287	0.00000	0.00703
3.307	2.03 * 10 ³	0.00134	0.00000	0.00323
3.387	2.44 * 10 ³	0.00129	0.00000	0.00316
4.038	1.09 * 10 ⁴	0.00000	NA	NA

7.1.4 Day 57 pseudoneutid80




Figure 7.4: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 7.4: Table of risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.403	2.53 * 10 ¹	0.00488	0.00306	0.00670
2.220	1.66 * 10 ²	0.00446	0.00259	0.00632
2.335	2.16 * 10 ²	0.00391	0.00219	0.00564
2.455	2.85 * 10 ²	0.00374	0.00199	0.00549
2.644	4.41 * 10 ²	0.00382	0.00183	0.00581
2.699	5.00 * 10 ²	0.00337	0.00131	0.00543
2.764	5.81 * 10 ²	0.00315	0.00093	0.00537
2.874	7.48 * 10 ²	0.00316	0.00038	0.00595
2.981	9.57 * 10 ²	0.00238	0.00002	0.00474
3.000	1.00 * 10 ³	0.00238	0.00002	0.00474
3.162	1.45 * 10 ³	0.00184	0.00000	0.00404
3.265	1.84 * 10 ³	0.00204	0.00000	0.00436
3.371	2.35 * 10 ³	0.00077	0.00000	0.00182
4.187	1.54 * 10 ⁴	0.00000	NA	NA

7.2 Plots and Tables with estimates and pointwise confidence intervals for Day 57 (monotone-corrected)

MOCK

7.2.1 Day 57 bindSpike




Figure 7.5: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.5: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.316	2.07×10^1	0.00491	0.00309	0.00673
2.699	5.00×10^2	0.00453	0.00266	0.00640
2.815	6.53×10^2	0.00450	0.00253	0.00647
2.982	9.59×10^2	0.00357	0.00190	0.00524
3.000	1.00×10^3	0.00357	0.00190	0.00524
3.113	1.30×10^3	0.00347	0.00175	0.00519
3.471	2.96×10^3	0.00266	0.00064	0.00467
3.658	4.55×10^3	0.00185	0.00000	0.00444
3.841	6.93×10^3	0.00148	0.00000	0.00474
4.006	1.01×10^4	0.00134	0.00000	0.01788
4.007	1.02×10^4	0.00134	0.00000	0.01788
4.007	1.02×10^4	0.00134	0.00000	0.01788
4.007	1.02×10^4	0.00134	0.00000	0.01788

7.2.2 Day 57 bindRBD




Figure 7.6: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.6: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.073	$1.18 * 10^1$	0.00487	0.00305	0.00668
2.699	$5.00 * 10^2$	0.00469	0.00274	0.00664
2.882	$7.62 * 10^2$	0.00462	0.00261	0.00663
3.000	$1.00 * 10^3$	0.00462	0.00261	0.00663
3.056	$1.14 * 10^3$	0.00408	0.00220	0.00597
3.259	$1.82 * 10^3$	0.00387	0.00193	0.00581
3.557	$3.61 * 10^3$	0.00372	0.00141	0.00604
3.797	$6.27 * 10^3$	0.00372	0.00000	0.00785
3.986	$9.68 * 10^3$	0.00372	0.00000	0.01251
4.186	$1.53 * 10^4$	0.00372	0.00000	0.02056
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950
4.211	$1.63 * 10^4$	0.00362	0.00000	0.03950

7.2.3 Day 57 pseudoneutid50




Figure 7.7: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.7: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.135	1.36 * 10 ¹	0.00484	0.00302	0.00666
2.055	1.14 * 10 ²	0.00448	0.00255	0.00642
2.177	1.50 * 10 ²	0.00448	0.00240	0.00657
2.281	1.91 * 10 ²	0.00448	0.00221	0.00675
2.519	3.30 * 10 ²	0.00406	0.00155	0.00658
2.657	4.54 * 10 ²	0.00315	0.00088	0.00542
2.699	5.00 * 10 ²	0.00315	0.00068	0.00563
2.828	6.73 * 10 ²	0.00315	0.00000	0.00634
2.959	9.10 * 10 ²	0.00315	0.00000	0.00700
3.000	1.00 * 10 ³	0.00283	0.00000	0.00649
3.174	1.49 * 10 ³	0.00283	0.00000	0.00699
3.307	2.03 * 10 ³	0.00134	0.00000	0.00323
3.387	2.44 * 10 ³	0.00129	0.00000	0.00316
4.038	1.09 * 10 ⁴	0.00000	NA	NA

7.2.4 Day 57 pseudoneutid80




Figure 7.8: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.8: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.403	$2.53 * 10^1$	0.00491	0.00310	0.00673
2.220	$1.66 * 10^2$	0.00446	0.00259	0.00632
2.335	$2.16 * 10^2$	0.00394	0.00221	0.00567
2.455	$2.85 * 10^2$	0.00374	0.00199	0.00549
2.644	$4.41 * 10^2$	0.00370	0.00171	0.00569
2.699	$5.00 * 10^2$	0.00341	0.00135	0.00547
2.764	$5.81 * 10^2$	0.00315	0.00093	0.00537
2.874	$7.48 * 10^2$	0.00312	0.00033	0.00590
2.981	$9.57 * 10^2$	0.00238	0.00002	0.00474
3.000	$1.00 * 10^3$	0.00238	0.00002	0.00474
3.162	$1.45 * 10^3$	0.00204	0.00000	0.00424
3.265	$1.84 * 10^3$	0.00204	0.00000	0.00435
3.371	$2.35 * 10^3$	0.00139	0.00035	0.00243
4.187	$1.54 * 10^4$	0.00000	NA	NA

7.3 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

7.3.1 Day 29 bindSpike




Figure 7.9: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.9: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.613	$4.10 * 10^0$	0.02823	0.02626	0.03021
1.805	$6.38 * 10^1$	0.02823	0.02626	0.03020
1.927	$8.45 * 10^1$	0.02823	0.02619	0.03027
2.081	$1.21 * 10^2$	0.02823	0.02603	0.03043
2.351	$2.24 * 10^2$	0.02823	0.02602	0.03044
2.522	$3.33 * 10^2$	0.02823	0.02546	0.03100
2.677	$4.75 * 10^2$	0.02823	0.02421	0.03226
2.699	$5.00 * 10^2$	0.02823	0.02421	0.03226
2.841	$6.93 * 10^2$	0.02823	0.02279	0.03367
3.000	$1.00 * 10^3$	0.02823	0.02402	0.03244
3.112	$1.29 * 10^3$	0.02823	0.02557	0.03090
3.252	$1.79 * 10^3$	0.02823	0.02718	0.02929
3.348	$2.23 * 10^3$	0.02823	0.02746	0.02900
4.007	$1.02 * 10^4$	0.00000	NA	NA

7.3.2 Day 29 bindRBD




Figure 7.10: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.10: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.834	$6.82 * 10^0$	0.00545	0.00348	0.00743
1.892	$7.80 * 10^1$	0.00511	0.00300	0.00721
2.098	$1.25 * 10^2$	0.00511	0.00296	0.00726
2.273	$1.87 * 10^2$	0.00485	0.00262	0.00708
2.575	$3.76 * 10^2$	0.00485	0.00248	0.00722
2.699	$5.00 * 10^2$	0.00485	0.00199	0.00772
2.780	$6.03 * 10^2$	0.00485	0.00178	0.00793
2.960	$9.12 * 10^2$	0.00485	0.00056	0.00914
3.000	$1.00 * 10^3$	0.00485	0.00069	0.00901
3.144	$1.39 * 10^3$	0.00485	0.00015	0.00955
3.461	$2.89 * 10^3$	0.00485	0.00000	0.00992
3.610	$4.07 * 10^3$	0.00485	0.00000	0.01107
3.736	$5.45 * 10^3$	0.00485	0.00000	0.01052
4.211	$1.63 * 10^4$	0.00427	0.00000	0.02582

7.3.3 Day 29 pseudoneutid50




Figure 7.11: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.11: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
	0.083 1.21 * 10 ⁰	0.00548	0.00350	0.00745
	0.779 6.01 * 10 ⁰	0.00494	0.00289	0.00699
	0.892 7.80 * 10 ⁰	0.00484	0.00277	0.00690
	0.988 9.73 * 10 ⁰	0.00484	0.00273	0.00694
	1.147 1.40 * 10 ¹	0.00479	0.00237	0.00722
	1.271 1.87 * 10 ¹	0.00423	0.00142	0.00704
	1.382 2.41 * 10 ¹	0.00410	0.00093	0.00727
	1.481 3.03 * 10 ¹	0.00410	0.00081	0.00740
	1.656 4.53 * 10 ¹	0.00410	0.00029	0.00792
	1.741 5.51 * 10 ¹	0.00410	0.00052	0.00768
	1.852 7.11 * 10 ¹	0.00410	0.00000	0.00831
	2.699 5.00 * 10 ²	0.00000	NA	NA
	2.879 7.57 * 10 ²	0.00000	NA	NA
	3.000 1.00 * 10 ³	0.00000	NA	NA

7.3.4 Day 29 pseudoneutid80




Figure 7.12: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.12: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.876	$7.52 * 10^0$	0.00555	0.00357	0.00752
0.876	$7.52 * 10^0$	0.00555	0.00357	0.00752
0.876	$7.52 * 10^0$	0.00555	0.00357	0.00752
1.183	$1.52 * 10^1$	0.00503	0.00299	0.00708
1.339	$2.18 * 10^1$	0.00500	0.00260	0.00739
1.440	$2.75 * 10^1$	0.00380	0.00157	0.00604
1.541	$3.48 * 10^1$	0.00293	0.00058	0.00528
1.632	$4.29 * 10^1$	0.00291	0.00003	0.00579
1.796	$6.25 * 10^1$	0.00239	0.00000	0.00563
1.868	$7.38 * 10^1$	0.00055	0.00000	0.00147
1.956	$9.04 * 10^1$	0.00055	0.00000	0.00157
2.699	$5.00 * 10^2$	0.00000	NA	NA
2.719	$5.24 * 10^2$	0.00000	NA	NA
3.000	$1.00 * 10^3$	0.00000	NA	NA

7.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

7.4.1 Day 29 bindSpike




Figure 7.13: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.13: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.613	$4.10 * 10^0$	0.02823	0.02626	0.03021
1.805	$6.38 * 10^1$	0.02823	0.02626	0.03020
1.927	$8.45 * 10^1$	0.02823	0.02619	0.03027
2.081	$1.21 * 10^2$	0.02823	0.02603	0.03043
2.351	$2.24 * 10^2$	0.02823	0.02602	0.03044
2.522	$3.33 * 10^2$	0.02823	0.02546	0.03100
2.677	$4.75 * 10^2$	0.02823	0.02421	0.03226
2.699	$5.00 * 10^2$	0.02823	0.02421	0.03226
2.841	$6.93 * 10^2$	0.02823	0.02279	0.03367
3.000	$1.00 * 10^3$	0.02823	0.02402	0.03244
3.112	$1.29 * 10^3$	0.02823	0.02557	0.03090
3.252	$1.79 * 10^3$	0.02823	0.02718	0.02929
3.348	$2.23 * 10^3$	0.02823	0.02746	0.02900
4.007	$1.02 * 10^4$	0.00000	NA	NA

7.4.2 Day 29 bindRBD




Figure 7.14: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.14: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.834	$6.82 * 10^0$	0.00545	0.00348	0.00743
1.892	$7.80 * 10^1$	0.00511	0.00300	0.00721
2.098	$1.25 * 10^2$	0.00511	0.00296	0.00726
2.273	$1.87 * 10^2$	0.00485	0.00262	0.00708
2.575	$3.76 * 10^2$	0.00485	0.00248	0.00722
2.699	$5.00 * 10^2$	0.00485	0.00199	0.00772
2.780	$6.03 * 10^2$	0.00485	0.00178	0.00793
2.960	$9.12 * 10^2$	0.00485	0.00056	0.00914
3.000	$1.00 * 10^3$	0.00485	0.00069	0.00901
3.144	$1.39 * 10^3$	0.00485	0.00015	0.00955
3.461	$2.89 * 10^3$	0.00485	0.00000	0.00992
3.610	$4.07 * 10^3$	0.00485	0.00000	0.01107
3.736	$5.45 * 10^3$	0.00485	0.00000	0.01052
4.211	$1.63 * 10^4$	0.00427	0.00000	0.02582

7.4.3 Day 29 pseudoneutid50




Figure 7.15: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.15: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with pointwise 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
	0.083 1.21 * 10 ⁰	0.00548	0.00350	0.00745
	0.779 6.01 * 10 ⁰	0.00494	0.00289	0.00699
	0.892 7.80 * 10 ⁰	0.00484	0.00277	0.00690
	0.988 9.73 * 10 ⁰	0.00484	0.00273	0.00694
	1.147 1.40 * 10 ¹	0.00479	0.00237	0.00722
	1.271 1.87 * 10 ¹	0.00423	0.00142	0.00704
	1.382 2.41 * 10 ¹	0.00410	0.00093	0.00727
	1.481 3.03 * 10 ¹	0.00410	0.00081	0.00740
	1.656 4.53 * 10 ¹	0.00410	0.00029	0.00792
	1.741 5.51 * 10 ¹	0.00410	0.00052	0.00768
	1.852 7.11 * 10 ¹	0.00410	0.00000	0.00831
	2.699 5.00 * 10 ²	0.00000	NA	NA
	2.879 7.57 * 10 ²	0.00000	NA	NA
	3.000 1.00 * 10 ³	0.00000	NA	NA

7.4.4 Day 29 pseudoneutid80




Figure 7.16: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.16: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with pointwise 95% confidence intervals.

log ₁₀ -Threshold	Threshold	Risk estimate	CI left	CI right
	0.876 7.52 * 10 ⁰	0.00555	0.00357	0.00752
	0.876 7.52 * 10 ⁰	0.00555	0.00357	0.00752
	0.876 7.52 * 10 ⁰	0.00555	0.00357	0.00752
	1.183 1.52 * 10 ¹	0.00503	0.00299	0.00708
	1.339 2.18 * 10 ¹	0.00500	0.00260	0.00739
	1.440 2.75 * 10 ¹	0.00380	0.00157	0.00604
	1.541 3.48 * 10 ¹	0.00293	0.00058	0.00528
	1.632 4.29 * 10 ¹	0.00291	0.00003	0.00579
	1.796 6.25 * 10 ¹	0.00239	0.00000	0.00563
	1.868 7.38 * 10 ¹	0.00055	0.00000	0.00147
	1.956 9.04 * 10 ¹	0.00055	0.00000	0.00157
	2.699 5.00 * 10 ²	0.00000	NA	NA
	2.719 5.24 * 10 ²	0.00000	NA	NA
	3.000 1.00 * 10 ³	0.00000	NA	NA

7.5 Plots and Tables with estimates and simultaneous confidence intervals for Day 57 (monotone-corrected)

MOCK

7.5.1 Day 57 bindSpike




Figure 7.17: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.17: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals.

log ₁₀ -Threshold	Threshold	Risk estimate	CI left	CI right
1.316	2.07 * 10 ¹	0.00491	0.00246	0.00735
2.699	5.00 * 10 ²	0.00453	0.00201	0.00705
2.815	6.53 * 10 ²	0.00450	0.00185	0.00715
2.982	9.59 * 10 ²	0.00357	0.00133	0.00582
3.000	1.00 * 10 ³	0.00357	0.00133	0.00582
3.113	1.30 * 10 ³	0.00347	0.00116	0.00578
3.471	2.96 * 10 ³	0.00266	0.00000	0.00537
3.658	4.55 * 10 ³	0.00185	0.00000	0.00533
3.841	6.93 * 10 ³	0.00148	0.00000	0.00586
4.006	1.01 * 10 ⁴	0.00134	0.00000	0.02361
4.007	1.02 * 10 ⁴	0.00134	0.00000	0.02361
4.007	1.02 * 10 ⁴	0.00134	0.00000	0.02361
4.007	1.02 * 10 ⁴	0.00134	0.00000	0.02361

7.5.2 Day 57 bindRBD




Figure 7.18: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.18: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.073	$1.18 * 10^1$	0.00487	0.00249	0.00725
2.699	$5.00 * 10^2$	0.00469	0.00214	0.00724
2.882	$7.62 * 10^2$	0.00462	0.00199	0.00725
3.000	$1.00 * 10^3$	0.00462	0.00199	0.00725
3.056	$1.14 * 10^3$	0.00408	0.00161	0.00656
3.259	$1.82 * 10^3$	0.00387	0.00133	0.00641
3.557	$3.61 * 10^3$	0.00372	0.00070	0.00675
3.797	$6.27 * 10^3$	0.00372	0.00000	0.00912
3.986	$9.68 * 10^3$	0.00372	0.00000	0.01523
4.186	$1.53 * 10^4$	0.00372	0.00000	0.02576
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059

7.5.3 Day 57 pseudoneutid50




Figure 7.19: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.19: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.135	1.36×10^1	0.00484	0.00223	0.00745
2.055	1.14×10^2	0.00448	0.00171	0.00726
2.177	1.50×10^2	0.00448	0.00149	0.00748
2.281	1.91×10^2	0.00448	0.00123	0.00774
2.519	3.30×10^2	0.00406	0.00046	0.00767
2.657	4.54×10^2	0.00315	0.00000	0.00641
2.699	5.00×10^2	0.00315	0.00000	0.00671
2.828	6.73×10^2	0.00315	0.00000	0.00772
2.959	9.10×10^2	0.00315	0.00000	0.00867
3.000	1.00×10^3	0.00283	0.00000	0.00808
3.174	1.49×10^3	0.00283	0.00000	0.00879
3.307	2.03×10^3	0.00134	0.00000	0.00405
3.387	2.44×10^3	0.00129	0.00000	0.00397
4.038	1.09×10^4	0.00000	NA	NA

7.5.4 Day 57 pseudoneutid80




Figure 7.20: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.20: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.403	2.53×10^1	0.00491	0.00231	0.00751
2.220	1.66×10^2	0.00446	0.00179	0.00712
2.335	2.16×10^2	0.00394	0.00147	0.00641
2.455	2.85×10^2	0.00374	0.00124	0.00624
2.644	4.41×10^2	0.00370	0.00085	0.00655
2.699	5.00×10^2	0.00341	0.00046	0.00635
2.764	5.81×10^2	0.00315	0.00000	0.00632
2.874	7.48×10^2	0.00312	0.00000	0.00710
2.981	9.57×10^2	0.00238	0.00000	0.00575
3.000	1.00×10^3	0.00238	0.00000	0.00575
3.162	1.45×10^3	0.00204	0.00000	0.00518
3.265	1.84×10^3	0.00204	0.00000	0.00535
3.371	2.35×10^3	0.00139	0.00000	0.00288
4.187	1.54×10^4	0.00000	NA	NA

7.6 Plots and Tables with estimates and simultaneous confidence intervals for Day 57 (monotone-corrected)

MOCK

7.6.1 Day 57 bindSpike




Figure 7.21: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.21: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindSpike levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.316	2.07×10^1	0.00491	0.00246	0.00735
2.699	5.00×10^2	0.00453	0.00201	0.00705
2.815	6.53×10^2	0.00450	0.00185	0.00715
2.982	9.59×10^2	0.00357	0.00133	0.00582
3.000	1.00×10^3	0.00357	0.00133	0.00582
3.113	1.30×10^3	0.00347	0.00116	0.00578
3.471	2.96×10^3	0.00266	0.00000	0.00537
3.658	4.55×10^3	0.00185	0.00000	0.00533
3.841	6.93×10^3	0.00148	0.00000	0.00586
4.006	1.01×10^4	0.00134	0.00000	0.02361
4.007	1.02×10^4	0.00134	0.00000	0.02361
4.007	1.02×10^4	0.00134	0.00000	0.02361
4.007	1.02×10^4	0.00134	0.00000	0.02361

7.6.2 Day 57 bindRBD




Figure 7.22: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.22: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57bindRBD levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.073	$1.18 * 10^1$	0.00487	0.00249	0.00725
2.699	$5.00 * 10^2$	0.00469	0.00214	0.00724
2.882	$7.62 * 10^2$	0.00462	0.00199	0.00725
3.000	$1.00 * 10^3$	0.00462	0.00199	0.00725
3.056	$1.14 * 10^3$	0.00408	0.00161	0.00656
3.259	$1.82 * 10^3$	0.00387	0.00133	0.00641
3.557	$3.61 * 10^3$	0.00372	0.00070	0.00675
3.797	$6.27 * 10^3$	0.00372	0.00000	0.00912
3.986	$9.68 * 10^3$	0.00372	0.00000	0.01523
4.186	$1.53 * 10^4$	0.00372	0.00000	0.02576
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059
4.211	$1.63 * 10^4$	0.00362	0.00000	0.05059

7.6.3 Day 57 pseudoneutid50




Figure 7.23: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.23: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid50 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.135	1.36×10^1	0.00484	0.00223	0.00745
2.055	1.14×10^2	0.00448	0.00171	0.00726
2.177	1.50×10^2	0.00448	0.00149	0.00748
2.281	1.91×10^2	0.00448	0.00123	0.00774
2.519	3.30×10^2	0.00406	0.00046	0.00767
2.657	4.54×10^2	0.00315	0.00000	0.00641
2.699	5.00×10^2	0.00315	0.00000	0.00671
2.828	6.73×10^2	0.00315	0.00000	0.00772
2.959	9.10×10^2	0.00315	0.00000	0.00867
3.000	1.00×10^3	0.00283	0.00000	0.00808
3.174	1.49×10^3	0.00283	0.00000	0.00879
3.307	2.03×10^3	0.00134	0.00000	0.00405
3.387	2.44×10^3	0.00129	0.00000	0.00397
4.038	1.09×10^4	0.00000	NA	NA

7.6.4 Day 57 pseudoneutid80




Figure 7.24: Adjusted threshold-response function for a range of thresholds of the Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.24: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Day57pseudoneutid80 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
1.403	$2.53 * 10^1$	0.00491	0.00231	0.00751
2.220	$1.66 * 10^2$	0.00446	0.00179	0.00712
2.335	$2.16 * 10^2$	0.00394	0.00147	0.00641
2.455	$2.85 * 10^2$	0.00374	0.00124	0.00624
2.644	$4.41 * 10^2$	0.00370	0.00085	0.00655
2.699	$5.00 * 10^2$	0.00341	0.00046	0.00635
2.764	$5.81 * 10^2$	0.00315	0.00000	0.00632
2.874	$7.48 * 10^2$	0.00312	0.00000	0.00710
2.981	$9.57 * 10^2$	0.00238	0.00000	0.00575
3.000	$1.00 * 10^3$	0.00238	0.00000	0.00575
3.162	$1.45 * 10^3$	0.00204	0.00000	0.00518
3.265	$1.84 * 10^3$	0.00204	0.00000	0.00535
3.371	$2.35 * 10^3$	0.00139	0.00000	0.00288
4.187	$1.54 * 10^4$	0.00000	NA	NA

7.7 Plots and Tables with estimates and simultaneous confidence intervals for Day 29 (monotone-corrected)

MOCK

7.7.1 Day 29 bindSpike




Figure 7.25: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.25: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.613	$4.10 * 10^0$	0.02823	0.02535	0.03111
1.805	$6.38 * 10^1$	0.02823	0.02536	0.03110
1.927	$8.45 * 10^1$	0.02823	0.02526	0.03120
2.081	$1.21 * 10^2$	0.02823	0.02503	0.03144
2.351	$2.24 * 10^2$	0.02823	0.02501	0.03146
2.522	$3.33 * 10^2$	0.02823	0.02419	0.03227
2.677	$4.75 * 10^2$	0.02823	0.02237	0.03410
2.699	$5.00 * 10^2$	0.02823	0.02237	0.03410
2.841	$6.93 * 10^2$	0.02823	0.02030	0.03616
3.000	$1.00 * 10^3$	0.02823	0.02210	0.03437
3.112	$1.29 * 10^3$	0.02823	0.02435	0.03211
3.252	$1.79 * 10^3$	0.02823	0.02669	0.02977
3.348	$2.23 * 10^3$	0.02823	0.02711	0.02935
4.007	$1.02 * 10^4$	0.00000	NA	NA

7.7.2 Day 29 bindRBD




Figure 7.26: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.26: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.834	$6.82 * 10^0$	0.00545	0.00266	0.00825
1.892	$7.80 * 10^1$	0.00511	0.00212	0.00809
2.098	$1.25 * 10^2$	0.00511	0.00206	0.00816
2.273	$1.87 * 10^2$	0.00485	0.00168	0.00802
2.575	$3.76 * 10^2$	0.00485	0.00149	0.00821
2.699	$5.00 * 10^2$	0.00485	0.00079	0.00892
2.780	$6.03 * 10^2$	0.00485	0.00049	0.00922
2.960	$9.12 * 10^2$	0.00485	0.00000	0.01094
3.000	$1.00 * 10^3$	0.00485	0.00000	0.01075
3.144	$1.39 * 10^3$	0.00485	0.00000	0.01152
3.461	$2.89 * 10^3$	0.00485	0.00000	0.01205
3.610	$4.07 * 10^3$	0.00485	0.00000	0.01368
3.736	$5.45 * 10^3$	0.00485	0.00000	0.01289
4.211	$1.63 * 10^4$	0.00427	0.00000	0.03484

7.7.3 Day 29 pseudoneutid50




Figure 7.27: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.27: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.083	$1.21 * 10^0$	0.00548	0.00270	0.00825
0.779	$6.01 * 10^0$	0.00494	0.00205	0.00783
0.892	$7.80 * 10^0$	0.00484	0.00192	0.00775
0.988	$9.73 * 10^0$	0.00484	0.00188	0.00779
1.147	$1.40 * 10^1$	0.00479	0.00138	0.00820
1.271	$1.87 * 10^1$	0.00423	0.00028	0.00819
1.382	$2.41 * 10^1$	0.00410	0.00000	0.00856
1.481	$3.03 * 10^1$	0.00410	0.00000	0.00874
1.656	$4.53 * 10^1$	0.00410	0.00000	0.00947
1.741	$5.51 * 10^1$	0.00410	0.00000	0.00914
1.852	$7.11 * 10^1$	0.00410	0.00000	0.01002
2.699	$5.00 * 10^2$	0.00000	NA	NA
2.879	$7.57 * 10^2$	0.00000	NA	NA
3.000	$1.00 * 10^3$	0.00000	NA	NA

7.7.4 Day 29 pseudoneutid80




Figure 7.28: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.28: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
1.183	$1.52 * 10^1$	0.00503	0.00215	0.00792
1.339	$2.18 * 10^1$	0.00500	0.00162	0.00837
1.440	$2.75 * 10^1$	0.00380	0.00065	0.00696
1.541	$3.48 * 10^1$	0.00293	0.00000	0.00624
1.632	$4.29 * 10^1$	0.00291	0.00000	0.00697
1.796	$6.25 * 10^1$	0.00239	0.00000	0.00695
1.868	$7.38 * 10^1$	0.00055	0.00000	0.00185
1.956	$9.04 * 10^1$	0.00055	0.00000	0.00199
2.699	$5.00 * 10^2$	0.00000	NA	NA
2.719	$5.24 * 10^2$	0.00000	NA	NA
3.000	$1.00 * 10^3$	0.00000	NA	NA

7.8 Plots and Tables with estimates and simultaneous confidence intervals for Day 29 (monotone-corrected)

MOCK

7.8.1 Day 29 bindSpike




Figure 7.29: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.29: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindSpike levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.613	$4.10 * 10^0$	0.02823	0.02535	0.03111
1.805	$6.38 * 10^1$	0.02823	0.02536	0.03110
1.927	$8.45 * 10^1$	0.02823	0.02526	0.03120
2.081	$1.21 * 10^2$	0.02823	0.02503	0.03144
2.351	$2.24 * 10^2$	0.02823	0.02501	0.03146
2.522	$3.33 * 10^2$	0.02823	0.02419	0.03227
2.677	$4.75 * 10^2$	0.02823	0.02237	0.03410
2.699	$5.00 * 10^2$	0.02823	0.02237	0.03410
2.841	$6.93 * 10^2$	0.02823	0.02030	0.03616
3.000	$1.00 * 10^3$	0.02823	0.02210	0.03437
3.112	$1.29 * 10^3$	0.02823	0.02435	0.03211
3.252	$1.79 * 10^3$	0.02823	0.02669	0.02977
3.348	$2.23 * 10^3$	0.02823	0.02711	0.02935
4.007	$1.02 * 10^4$	0.00000	NA	NA

7.8.2 Day 29 bindRBD




Figure 7.30: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.30: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29bindRBD levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.834	$6.82 * 10^0$	0.00545	0.00266	0.00825
1.892	$7.80 * 10^1$	0.00511	0.00212	0.00809
2.098	$1.25 * 10^2$	0.00511	0.00206	0.00816
2.273	$1.87 * 10^2$	0.00485	0.00168	0.00802
2.575	$3.76 * 10^2$	0.00485	0.00149	0.00821
2.699	$5.00 * 10^2$	0.00485	0.00079	0.00892
2.780	$6.03 * 10^2$	0.00485	0.00049	0.00922
2.960	$9.12 * 10^2$	0.00485	0.00000	0.01094
3.000	$1.00 * 10^3$	0.00485	0.00000	0.01075
3.144	$1.39 * 10^3$	0.00485	0.00000	0.01152
3.461	$2.89 * 10^3$	0.00485	0.00000	0.01205
3.610	$4.07 * 10^3$	0.00485	0.00000	0.01368
3.736	$5.45 * 10^3$	0.00485	0.00000	0.01289
4.211	$1.63 * 10^4$	0.00427	0.00000	0.03484

7.8.3 Day 29 pseudoneutid50




Figure 7.31: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.31: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid50 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.083	$1.21 * 10^0$	0.00548	0.00270	0.00825
0.779	$6.01 * 10^0$	0.00494	0.00205	0.00783
0.892	$7.80 * 10^0$	0.00484	0.00192	0.00775
0.988	$9.73 * 10^0$	0.00484	0.00188	0.00779
1.147	$1.40 * 10^1$	0.00479	0.00138	0.00820
1.271	$1.87 * 10^1$	0.00423	0.00028	0.00819
1.382	$2.41 * 10^1$	0.00410	0.00000	0.00856
1.481	$3.03 * 10^1$	0.00410	0.00000	0.00874
1.656	$4.53 * 10^1$	0.00410	0.00000	0.00947
1.741	$5.51 * 10^1$	0.00410	0.00000	0.00914
1.852	$7.11 * 10^1$	0.00410	0.00000	0.01002
2.699	$5.00 * 10^2$	0.00000	NA	NA
2.879	$7.57 * 10^2$	0.00000	NA	NA
3.000	$1.00 * 10^3$	0.00000	NA	NA

7.8.4 Day 29 pseudoneutid80




Figure 7.32: Adjusted threshold-response function for a range of thresholds of the Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.32: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Day29pseudoneutid80 levels with simultaneous 95% confidence intervals.

\log_{10} -Threshold	Threshold	Risk estimate	CI left	CI right
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
0.876	$7.52 * 10^0$	0.00555	0.00277	0.00833
1.183	$1.52 * 10^1$	0.00503	0.00215	0.00792
1.339	$2.18 * 10^1$	0.00500	0.00162	0.00837
1.440	$2.75 * 10^1$	0.00380	0.00065	0.00696
1.541	$3.48 * 10^1$	0.00293	0.00000	0.00624
1.632	$4.29 * 10^1$	0.00291	0.00000	0.00697
1.796	$6.25 * 10^1$	0.00239	0.00000	0.00695
1.868	$7.38 * 10^1$	0.00055	0.00000	0.00185
1.956	$9.04 * 10^1$	0.00055	0.00000	0.00199
2.699	$5.00 * 10^2$	0.00000	NA	NA
2.719	$5.24 * 10^2$	0.00000	NA	NA
3.000	$1.00 * 10^3$	0.00000	NA	NA

MOCK

Chapter 8

Univariate CoR: Nonparametric Threshold Modeling ($\leq s$)

The same methodology as the previous section is apply to estimate the “below” threshold-response function $E_W E[Y = 1 | A = 1, X, S \leq s]$.

MOCHI

MOCK

Chapter 9

Day D29 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models with degrees of freedom selected by cross-validation using the mgcv R package.




Figure 9.1: Marginalized risk as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3.

Binding Antibody to RBD: Day 29




Figure 9.2: Marginalized risk as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.




Figure 9.3: Marginalized risk as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 2.4.

PsV Neutralization 80% Titer: Day 29




Figure 9.4: Marginalized risk as functions of Day 29 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 15.

MOCK

Chapter 10

Day D57 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models with degrees of freedom selected by cross-validation using the mgcv R package.




Figure 10.1: Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3.

Binding Antibody to RBD: Day 57




Figure 10.2: Marginalized risk as functions of Day 57 markers (=s) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 1.6.




Figure 10.3: Marginalized risk as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 2.4.

PsV Neutralization 80% Titer: Day 57




Figure 10.4: Marginalized risk as functions of Day 57 markers ($=s$) among vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: MinorityInd + HighRiskInd + riskscore. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 15.

MOCK

Chapter 11

Appendix

- This report was built from the [CoVPN/correlates_reporting](#) repository with commit hash fab976fef998984a9e343a0e1586f71c4f73afbf. A diff of the changes introduced by that commit may be viewed at https://github.com/CoVPN/correlates_reporting/commit/fab976fef998984a9e343a0e1586f71c4f73afbf
- The sha256 hash sum of the raw input file, “COVID_VEtiral_practicedata_primarystage1.csv”: 83d0f55d1745ffd42be124d8f9ec9a9903abcc13cd22f95e537542a08b41300a
- The sha256 hash sum of the processed file, “moderna_mock_data_processed.csv”: d806a7fb38690eff7ecb69f0bd6f74afc5